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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/
10.1111/bph.13353/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated
ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the
best available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets.
It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented
in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification
and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable,
point-in-time record that will survive database updates.
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Overview: Catalytic receptors are cell-surface proteins, usually
dimeric in nature, which encompass ligand binding and func-
tional domains in one polypeptide chain. The ligand binding
domain is placed on the extracellular surface of the plasma mem-
brane and separated from the functional domain by a single
transmembrane-spanning domain of 20-25 hydrophobic amino
acids. The functional domain on the intracellular face of the
plasma membrane has catalytic activity, or interacts with partic-
ular enzymes, giving the superfamily of receptors its name. En-
dogenous agonists of the catalytic receptor superfamily are pep-
tides or proteins, the binding of which may induce dimerization
of the receptor, which is the functional version of the receptor.
Amongst the catalytic receptors, particular subfamilies may be
readily identified dependent on the function of the enzymatic
portion of the receptor. The smallest group is the particulate
guanylyl cyclases of the natriuretic peptide receptor family. The
most widely recognized group is probably the receptor tyrosine
kinase (RTK) family, epitomized by the neurotrophin receptor
family, where a crucial initial step is the activation of a signalling
cascade by autophosphorylation of the receptor on intracellular
tyrosine residue(s) catalyzed by enzyme activity intrinsic to the
receptor. A third group is the extrinsic protein tyrosine kinase
receptors, where the catalytic activity resides in a separate pro-
tein from the binding site. Examples of this group include the
GDNF and ErbB receptor families, where one, catalytically silent,
member of the heterodimer is activated upon binding the ligand,
causing the second member of the heterodimer, lacking ligand
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binding capacity, to initiate signaling through tyrosine phos-
phorylation. A fourth group, the receptor threonine/serine ki-
nase (RTSK) family, exemplified by TGF-β and BMP receptors,
has intrinsic serine/threonine protein kinase activity in the het-
erodimeric functional unit. A fifth group is the receptor ty-
rosine phosphatases (RTP), which appear to lack cognate lig-
ands, but may be triggered by events such as cell:cell contact
and have identified roles in the skeletal, hematopoietic and
immune systems.
A sixth group of catalytic receptors in the Guide is the integrins,
which have roles in cell:cell communication, often associated
with signaling in the blood.
Family structure
5981 Cytokine receptor family
5981 IL-2 receptor family
5983 IL-3 receptor family
5983 IL-6 receptor family
5985 IL-12 receptor family
5985 Prolactin receptor family
5986 Interferon receptor family
5987 IL-10 receptor family
5988 Immunoglobulin-like family of IL-1 receptors
5989 IL-17 receptor family
5990 GDNF receptor family
5991 Integrins
5994 Natriuretic peptide receptor family
5996 Pattern recognition receptors
5996 Toll-like receptor family
5997 NOD-like receptor family
– Receptor kinases
– Other protein kinases
– TK: Tyrosine kinase
5999 Receptor serine/threonine kinase (RSTK) family
6000 Type I receptor serine/threonine kinases
6001 Type II receptor serine/threonine kinases
6001 Type III receptor serine/threonine kinases
6002 RSTK functional heteromers
6003 Receptor tyrosine kinases
6004 Type I RTKs: ErbB (epidermal growth factor)
receptor family
6005 Type II RTKs: Insulin receptor family
6005 Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
6007 Type IV RTKs: VEGF (vascular endothelial growth factor)
receptor family
6008 Type V RTKs: FGF (fibroblast growth factor)
receptor family
6008 Type VI RTKs: PTK7/CCK4
6009 Type VII RTKs: Neurotrophin receptor/Trk family
6010 Type VIII RTKs: ROR family
6010 Type IX RTKs: MuSK
6010 Type X RTKs: HGF (hepatocyte growth factor)
receptor family
6011 Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK)
receptor family
6012 Type XII RTKs: TIE family of angiopoietin receptors
6012 Type XIII RTKs: Ephrin receptor family
6013 Type XIV RTKs: RET
6014 Type XV RTKs: RYK
6014 Type XVI RTKs: DDR (collagen receptor) family
6015 Type XVII RTKs: ROS receptors
6015 Type XVIII RTKs: LMR family
6016 Type XIX RTKs: Leukocyte tyrosine kinase (LTK)
receptor family
6016 Type XX RTKs: STYK1
– TKL: Tyrosine kinase-like
6017 Receptor tyrosine phosphatases (RTP)
6018 Tumour necrosis factor (TNF) receptor family
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Cytokine receptor family
Catalytic receptors! Cytokine receptor family
Overview: Cytokines are not a clearly defined group of agents,
other than having an impact on immune signalling pathways, al-
though many cytokines have effects on other systems, such as in
development. A feature of some cytokines, which allows them
to be distinguished from hormones, is that they may be pro-
duced by “non-secretory” cells, for example, endothelial cells.
Within the cytokine receptor family, some subfamilies may be
identified, which are described elsewhere in the Guide to PHAR-
MACOLOGY, receptors for the TNF family, the TGF-β family and
the chemokines. Within this group of records are described Type
I cytokine receptors, typified by interleukin receptors, and Type II
cytokine receptors, exemplified by interferon receptors. These re-
ceptors possess a conserved extracellular region, known as the cy-
tokine receptor homology domain (CHD), along with a range of
other structural modules, including extracellular immunoglobu-
lin (Ig)-like and fibronectin type III (FBNIII)-like domains, a trans-
membrane domain, and intracellular homology domains. An un-
usual feature of this group of agents is the existence of soluble
and decoy receptors. These bind cytokines without allowing sig-
nalling to occur. A further attribute is the production of endoge-
nous antagonist molecules, which bind to the receptors selec-
tively and prevent signalling. A commonality of these families of
receptors is the ligand-induced homo- or hetero-oligomerisation,
which results in the recruitment of intracellular protein part-
ners to evoke cellular responses, particularly in inflammatory or
haematopoietic signalling. Although not an exclusive signalling
pathway, a common feature of the majority of cytokine recep-
tors is activation of the JAK/STAT pathway. This cascade is based
around the protein tyrosine kinase activity of the Janus kinases
(JAK), which phosphorylate the receptor and thereby facilitate
the recruitment of signal transducers and activators of transcrip-
tion (STATs). The activated homo- or heterodimeric STATs func-
tion principally as transcription factors in the nucleus.
Type I cytokine receptors are characterized by two pairs of
conserved cysteines linked via disulfide bonds and a C-terminal
WSXWS motif within their CHD. Type I receptors are commonly
classified into five groups, based on sequence and structual ho-
mology of the receptor and its cytokine ligand, which is poten-
tially more reflective of evolutionary relationships than an earlier
scheme based on the use of common signal transducing chains
within a receptor complex. These are the IL-2, IL-3, IL-6, IL-12
and prolactin families.
Type II cytokine receptors also have two pairs of conserved
cysteines but with a different arrangement to Type I and also lack
the WSXWS motif. The type II cytokine receptors include the in-
terferon, IL-10, IL-1 and IL-17 receptors.
IL-2 receptor family
Catalytic receptors! Cytokine receptor family! IL-2 receptor family
Overview: The IL-2 receptor family consists of one or more ligand-selective subunits, and a common γ chain (γc): IL2RG, P31785), though IL-4 and IL-7 receptors can form complexes with other receptor
chains. Receptors of this family associate with Jak1 and Jak3, primarily activating Stat5, although certain family members can also activate Stat1, Stat3, or Stat6. Ro264550 has been described as a selective
IL-2 receptor antagonist, which binds to IL-2 [177].
Nomenclature Interleukin-2 receptor Interleukin-4 receptor type I Interleukin-4 receptor type II Interleukin-7 receptor Interleukin-9 receptor
Subunits Interleukin-2 receptor subunit β
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit),
Interleukin-2 receptor subunit α
(Ligand-binding subunit)
Interleukin-4 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)
Interleukin-13 receptor subunit α1
(Other subunit),
Interleukin-4 receptor subunit α
(Ligand-binding subunit)
Interleukin-2 receptor subunit γ
(Other subunit),
Interleukin-7 receptor subunit α
(Ligand-binding subunit)
Interleukin-2 receptor subunit γ
(Other subunit),
Interleukin 9 receptor
(Ligand-binding subunit)
Endogenous agonists IL-2 (IL2, P60568) IL-4 (IL4, P05112) IL-13 (IL13, P35225), IL-4 (IL4,
P05112)
IL-7 (IL7, P13232) IL-9 (IL9, P15248)
Endogenous antagonists IL-1 receptor antagonist (IL1RN,
P18510)
– – – –
Antagonists Ro26-4550 [177] – – – –
Selective antagonists AF12198 [3] – – – –
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Nomenclature Interleukin 13 receptor, α2 Interleukin-15 receptor Interleukin-21 receptor Thymic stromal lymphopoietin receptor
HGNC, UniProt IL13RA2, Q14627 – – –
Subunits – Interleukin-2 receptor subunit β
(Ligand-binding subunit),
Interleukin-15 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ (Other
subunit)
Interleukin-2 receptor subunit γ (Other
subunit), Interleukin 21 receptor
(Ligand-binding subunit)
Cytokine receptor-like factor 2 (Other
subunit), Interleukin-7 receptor subunit α
(Ligand-binding subunit)
Endogenous agonists – IL-15 (IL15, P40933) IL-21 (IL21, Q9HBE4) thymic stromal lymphopoietin (TSLP,
Q969D9)
Comments Decoy receptor that binds IL-13 (IL13,
P35225) as a monomer.
– – –
Subunits
Nomenclature Interleukin-2 receptor subunit α Interleukin-2 receptor subunit β Interleukin-2 receptor subunit γ Interleukin-4 receptor subunit α Interleukin-7 receptor subunit α
HGNC, UniProt IL2RA, P01589 IL2RB, P14784 IL2RG, P31785 IL4R, P24394 IL7R, P16871
Antibodies daclizumab (Binding) (pKd >8)
[154], basiliximab (Binding)
– – dupilumab (Binding) (pIC50 11.1)
[121]
–
Nomenclature Interleukin 9 receptor Interleukin-13 receptor subunit α1 Interleukin-15 receptor subunit α Interleukin 21 receptor Cytokine receptor-like factor 2
HGNC, UniProt IL9R, Q01113 IL13RA1, P78552 IL15RA, Q13261 IL21R, Q9HBE5 CRLF2, Q9HC73
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IL-3 receptor family
Catalytic receptors! Cytokine receptor family! IL-3 receptor family
Overview: The IL-3 receptor family signal through a receptor complex comprising of a ligand-specific α subunit and a common β chain (CSF2RB, P32927), which is associated with Jak2 and signals
primarily through Stat5.
Nomenclature Interleukin-3 receptor Interleukin-5 receptor Granulocyte macrophage colony-stimulating factor receptor
Subunits Interleukin 3 receptor, α subunit
(Ligand-binding subunit),
Cytokine receptor common β subunit
(Other subunit)
Interleukin 5 receptor, α subunit
(Ligand-binding subunit),
Cytokine receptor common β subunit
(Other subunit)
GM-CSF receptor, α subunit (Ligand-binding subunit),
Cytokine receptor common β subunit (Other subunit)
Endogenous
agonists
IL-3 (IL3, P08700) IL-5 (IL5, P05113) G-CSF (CSF3, P09919), GM-CSF (CSF2, P04141)
Selective
antagonists
– YM90709 [133] –
Subunits
Nomenclature Interleukin 3 receptor, α subunit Interleukin 5 receptor, α subunit GM-CSF receptor, α subunit Cytokine receptor common β subunit
HGNC, UniProt IL3RA, P26951 IL5RA, Q01344 CSF2RA, P15509 CSF2RB, P32927
Endogenous agonists IL-3 (IL3, P08700) IL-5 (IL5, P05113) GM-CSF (CSF2, P04141) –
Antibodies – benralizumab (Binding) (pKd 8.7) [93] mavrilimumab (Binding) (pIC50 9.9) [29] –
IL-6 receptor family
Catalytic receptors! Cytokine receptor family! IL-6 receptor family
Overview: The IL-6 receptor family signal through a ternary receptor complex consisting of the cognate receptor and either the IL-6 signal transducer gp130 (IL6ST, P40189) or the oncostatin M-specific
receptor, β subunit (OSMR, Q99650), which then activates the JAK/STAT, Ras/Raf/MAPK and PI 3-kinase/PKB signalling modules. Unusually amongst the cytokine receptors, the CNTF receptor is a
glycerophosphatidylinositol-linked protein.
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Nomenclature Interleukin-6 receptor Interleukin-11 receptor Interleukin-31 receptor Ciliary neutrophic factor receptor
Subunits Interleukin-6 receptor, α subunit
(Ligand-binding subunit),
Interleukin-6 receptor, β subunit (Other
subunit)
Interleukin-11 receptor, α subunit
(Ligand-binding subunit),
Interleukin-6 receptor, β subunit (Other
subunit)
Interleukin-31 receptor, α subunit
(Ligand-binding subunit),
Oncostatin M-specific receptor, β subunit
(Other subunit)
Leukemia inhibitory factor receptor (Other
subunit), Interleukin-6 receptor, β subunit,
Ciliary neurotrophic factor receptor α subunit
(Ligand-binding subunit)
Endogenous
agonists
IL-6 (IL6, P05231) IL-11 (IL11, P20809) IL-31 (IL31, Q6EBC2) CRCF1/CLCF1 heterodimer (CLCF1 CRLF1,
O75462 Q9UBD9),
ciliary neurotrophic factor (CNTF, P26441)
Agonists – oprelvekin – –
Antibodies tocilizumab (Binding) (pKd 8.6) – – –
Nomenclature Leptin receptor Leukemia inhibitory factor receptor Oncostatin-M receptor Interleukin-27 receptor
HGNC, UniProt LEPR, P48357 – – –
Subunits – Leukemia inhibitory factor receptor
(Ligand-binding subunit),
Interleukin-6 receptor, β subunit (Other
subunit)
Interleukin-6 receptor, β subunit (Other
subunit),
Oncostatin M-specific receptor, β subunit
(Ligand-binding subunit)
Interleukin-6 receptor, β subunit
(Other subunit),
Interleukin 27 receptor, alpha
(Ligand-binding subunit)
Endogenous agonists leptin (LEP, P41159) LIF (LIF, P15018), cardiotrophin-1 (CTF1,
Q16619), oncostatin M (OSM, P13725)
oncostatin M (OSM, P13725) IL-27 (EBI3 IL27, Q14213
Q8NEV9)
Subunits
Nomenclature Interleukin-6 receptor, α subunit Interleukin-6 receptor, β subunit Interleukin-11 receptor, α subunit Interleukin 27 receptor, alpha
HGNC, UniProt IL6R, P08887 IL6ST, P40189 IL11RA, Q14626 IL27RA, Q6UWB1
Antibodies sarilumab (Binding) (pKd
10.6–11.1) [171]
– – –
Nomenclature Interleukin-31 receptor, α subunit Ciliary neurotrophic factor receptor α subunit Leukemia inhibitory factor receptor Oncostatin M-specific receptor, β subunit
HGNC, UniProt IL31RA, Q8NI17 CNTFR, P26992 LIFR, P42702 OSMR, Q99650
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IL-12 receptor family
Catalytic receptors! Cytokine receptor family! IL-12 receptor family
Overview: IL-12 receptors are a subfamily of the IL-6 receptor family. IL12RB1 is shared between receptors for IL-12 and IL-23; the functional agonist at IL-12 receptors is a heterodimer of IL-12A/IL-12B,
while that for IL-23 receptors is a heterodimer of IL-12B/IL-23A.
Nomenclature Interleukin-12 receptor Interleukin-23 receptor Interleukin-12 receptor, β1
subunit
Interleukin-12 receptor, β2
subunit
Interleukin 23 receptor
HGNC, UniProt – – IL12RB1, P42701 IL12RB2, Q99665 IL23R, Q5VWK5
Subunits Interleukin-12 receptor, β2 subunit
(Other subunit),
Interleukin-12 receptor, β1 subunit
(Ligand-binding subunit)
Interleukin 23 receptor (Ligand-binding
subunit),
Interleukin-12 receptor, β1 subunit
(Ligand-binding subunit)
– – –
Endogenous agonists IL-12 (IL12A IL12B, P29459 P29460) IL-23 (IL12B IL23A, P29460) – – –
Prolactin receptor family
Catalytic receptors! Cytokine receptor family! Prolactin receptor family
Overview: Prolactin family receptors form homodimers in the presence of their respective ligands, associate exclusively with Jak2 and signal via Stat5.
Nomenclature Eythropoietin receptor Granulocyte colony-stimulating
factor receptor
Growth hormone receptor Prolactin receptor Thrombopoietin receptor
HGNC, UniProt EPOR, P19235 CSF3R, Q99062 GHR, P10912 PRLR, P16471 MPL, P40238
Endogenous agonists erythropoietin (EPO, P01588)
(Selective) (pIC50 11.1) [48]
G-CSF (CSF3, P09919) growth hormone 1 (GH1,
P01241), growth hormone 2
(GH2, P01242)
choriomammotropin (CSH1 CSH2,
P01243),
chorionic somatomammotropin
hormone-like 1
(CSHL1, Q14406), prolactin (PRL,
P01236)
thrombopoietin (THPO, P40225)
Agonists peginesatide (pIC50 10.4) [48] pegfilgrastim – – romiplostim
Selective agonists – – – – eltrombopag (pEC50 7.4) [119]
Antagonists – – pegvisomant [180] – –
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Interferon receptor family
Catalytic receptors! Cytokine receptor family! Interferon receptor family
Overview: The interferon receptor family includes receptors for
type I (α, β  and !) and type II (γ) interferons. There are at least
13 different genes encoding IFN-α subunits in a cluster on human
chromosome 9p22: α1 (IFNA1, P01562), α2 (IFNA2, P01563), α4
(IFNA4, P05014), α5 (IFNA5, P01569), α6 (IFNA6, P05013), α7
(IFNA7, P01567), α8 (IFNA8, P32881), α10 (IFNA10, P01566), α13
(IFNA13, P01562), α14 (IFNA14, P01570), α16 (IFNA16, P05015),
α17 (IFNA17, P01571) and α21 (IFNA21, P01568).
Nomenclature Interferon-α/β receptor Interferon-γ receptor
Subunits Interferon α/β receptor 2 (Other subunit), interferon α/β receptor 1 (Ligand-binding
subunit)
Interferon γ receptor 2 (Other subunit), Interferon γ receptor 1 (Ligand-binding
subunit)
Endogenous
agonists
IFN-α1/13 (IFNA1 IFNA13, P01562), IFN-α10 (IFNA10, P01566), IFN-α14 (IFNA14,
P01570), IFN-α16 (IFNA16, P05015), IFN-α17 (IFNA17, P01571), IFN-α2 (IFNA2,
P01563), IFN-α21 (IFNA21, P01568), IFN-α4 (IFNA4, P05014), IFN-α5 (IFNA5,
P01569), IFN-α6 (IFNA6, P05013), IFN-α7 (IFNA7, P01567), IFN-α8 (IFNA8, P32881),
IFN-β (IFNB1, P01574), IFN- (IFNK, Q9P0W0), IFN-! (IFNW1, P05000)
IFN-γ (IFNG, P01579)
Selective agonists peginterferon alfa-2b [191] –
Subunits
Nomenclature interferon α/β receptor 1 Interferon α/β receptor 2 Interferon γ receptor 1 Interferon γ receptor 2
HGNC, UniProt IFNAR1, P17181 IFNAR2, P48551 IFNGR1, P15260 IFNGR2, P38484
Selective agonists peginterferon alfa-2b [191] – – –
Antibodies anifrolumab (Binding) (pKd >10) [21] – – –
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IL-10 receptor family
Catalytic receptors! Cytokine receptor family! IL-10 receptor family
Overview: The IL-10 family of receptors are heterodimeric combinations of family members: IL10RA/IL10RB responds to IL-10; IL20RA/IL20RB responds to IL-19, IL-20 and IL-24; IL22RA1/IL20RB
responds to IL-20 and IL-24; IL22RA1/IL10RB responds to IL-22; IL28RA/IL10RB responds to IL-28A, IL28B and IL-29.
Nomenclature Interleukin-10 receptor Interleukin-20 receptor Interleukin-22α1/20β
heteromer
Interleukin-22α1/10β
heteromer
Interleukin-22 receptor α2 Interferon- receptor 1
HGNC, UniProt – – – – IL22RA2, Q969J5 –
Subunits
Interleukin 10 receptor,
α subunit
(Ligand-binding subunit),
Interleukin 10 receptor,
β subunit
(Other subunit)
Interleukin 20 receptor,
β subunit
(Other subunit),
Interleukin 20 receptor,
α subunit
(Ligand-binding subunit)
Interleukin 22 receptor,
α1 subunit
(Ligand-binding subunit),
Interleukin 20 receptor,
β subunit
(Ligand-binding subunit)
Interleukin 22 receptor,
α1 subunit
(Ligand-binding subunit),
Interleukin 10 receptor,
β subunit
(Ligand-binding subunit)
–
Interferon- receptor subunit 1
(Ligand-binding subunit),
Interleukin 10 receptor,
β subunit
(Other subunit)
Endogenous
agonists
IL-10 (IL10, P22301) IL-19 (IL19, Q9UHD0), IL-20
(IL20, Q9NYY1), IL-24 (IL24,
Q13007)
IL-20 (IL20, Q9NYY1), IL-24
(IL24, Q13007)
IL-22 (IL22, Q9GZX6) – IFN-1 (IFNL1, Q8IU54),
IFN-2 (IFNL2, Q8IZJ0),
IFN-3 (IFNL3, Q8IZI9)
Comments – – – – Soluble decoy receptor that
binds IL-22 (IL22, Q9GZX6) as
a monomer.
–
Subunits
Nomenclature Interleukin 10 receptor,
α subunit
Interleukin 10 receptor,
β subunit
Interleukin 20 receptor,
α subunit
Interleukin 20 receptor,
β subunit
Interleukin 22 receptor,
α1 subunit
Interferon-
receptor subunit 1
HGNC, UniProt IL10RA, Q13651 IL10RB, Q08334 IL20RA, Q9UHF4 IL20RB, Q6UXL0 IL22RA1, Q8N6P7 IFNLR1, Q8IU57
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Immunoglobulin-like family of IL-1 receptors
Catalytic receptors! Cytokine receptor family! Immunoglobulin-like family of IL-1 receptors
Overview: The immunoglobulin-like family of IL-1 receptors are heterodimeric receptors made up of a cognate receptor subunit and an IL-1 receptor accessory protein, IL1RAP (Q9NPH3, also known as
C3orf13, IL-1RAcP, IL1R3). They are characterised by extracellular immunoglobulin-like domains and an intracellular Toll/Interleukin-1R (TIR) domain.
Nomenclature Interleukin-1 receptor, type I Interleukin-33 receptor Interleukin-36 receptor Interleukin-1 receptor, type II Interleukin-18 receptor
Subunits IL-1 receptor accessory protein
(Other subunit),
Interleukin 1 receptor, type I
(Ligand-binding subunit)
IL-1 receptor accessory protein
(Other subunit),
Interleukin-1 receptor-like 1
(Ligand-binding subunit)
IL-1 receptor accessory protein
(Other subunit),
Interleukin-1 receptor-like 2
(Ligand-binding subunit)
IL-1 receptor accessory protein
(Other subunit),
Interleukin 1 receptor, type II
(Ligand-binding subunit)
IL-18 receptor accessory protein
(Other subunit),
Interleukin-18 1 (Ligand-binding subunit)
Inhibitors anakinra (pKd 7.8) [44] – – – –
Endogenous
agonists
IL-1α (IL1A, P01583), IL-1β (IL1B,
P01584)
IL-33 (IL33, O95760) IL-36α (IL36A, Q9UHA7), IL-36β
(IL36B, Q9NZH7), IL-36γ (IL36G,
Q9NZH8)
– IL-18 (IL18, Q14116), IL-37 (IL37,
Q9NZH6)
Endogenous
antagonists
IL-1 receptor antagonist (IL1RN,
P18510)
– IL-36 receptor antagonist (IL36RN,
Q9UBH0)
– –
Selective
antagonists
AF12198 [3] – – – –
Comments – – IL-36 receptor antagonist (IL36RN,
Q9UBH0) is a highly specific
antagonist of the response to
IL-36γ (IL36G, Q9NZH8).
Decoy receptor that binds IL-1α
(IL1A, P01583), IL-1β (IL1B,
P01584) and
IL-1 receptor antagonist (IL1RN,
P18510).
–
Subunits
Nomenclature Interleukin 1 receptor, type I Interleukin 1 receptor, type II Interleukin-1 receptor-like 1 Interleukin-1 receptor-like 2 Interleukin-18 1
HGNC, UniProt IL1R1, P14778 IL1R2, P27930 IL1RL1, Q01638 IL1RL2, Q9HB29 IL18R1, Q13478
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IL-17 receptor family
Catalytic receptors! Cytokine receptor family! IL-17 receptor family
Overview: The IL17 cytokine family consists of six ligands (IL-17A-F), which signal through five receptors (IL-17RA-E).
Nomenclature Interleukin-17 receptor Interleukin-25 receptor Interleukin-17C receptor
Subunits Interleukin 17 receptor A
(Ligand-binding subunit),
interleukin 17 receptor C
(Other subunit)
Interleukin 17 receptor B
(Ligand-binding subunit),
Interleukin 17 receptor A
(Other subunit)
Interleukin 17 receptor A
(Other subunit),
Interleukin 17 receptor E
(Ligand-binding subunit)
Endogenous agonists IL-17A (IL17A, Q16552), IL-17A/IL-17F (IL17A
IL17F, Q16552 Q96PD4), IL-17F (IL17F, Q96PD4)
IL-17B (IL17B, Q9UHF5), IL-25 (IL25, Q9H293) IL-17C (IL17C, Q9P0M4)
Subunits
Nomenclature Interleukin 17 receptor A Interleukin 17 receptor B interleukin 17 receptor C Interleukin-17 receptor D Interleukin 17 receptor E
HGNC, UniProt IL17RA, Q96F46 IL17RB, Q9NRM6 IL17RC, Q8NAC3 IL17RD, Q8NFM7 IL17RE, Q8NFR9
Antibodies brodalumab (Binding)
(pKd 9.2) [179]
– – – –
Comments – – – The endogenous agonist
for this receptor is
unknown.
–
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GDNF receptor family
Catalytic receptors! GDNF receptor family
Overview: GDNF family receptors (provisional nomenclature) are extrinsic tyrosine kinase receptors. Ligand binding to the extracellular domain of the glycosylphosphatidylinositol-linked cell-surface
receptors (tabulated below) activates a transmembrane tyrosine kinase enzyme, RET (see Receptor Tyrosine Kinases). The endogenous ligands are typically dimeric, linked through disulphide bridges: glial
cell-derived neurotrophic factor GDNF (GDNF, P39905) (211 aa); neurturin (NRTN, Q99748) (197 aa); artemin (ARTN, Q5T4W7) (237 aa) and persephin (PSPN, O60542) (PSPN, 156 aa).
Nomenclature GDNF family receptor α1 GDNF family receptor α2 GDNF family receptor α3 GDNF family receptor α4
Common abreviation GFRα1 GFRα2 GFRα3 GFRα4
HGNC, UniProt GFRA1, P56159 GFRA2, O00451 GFRA3, O60609 GFRA4, Q9GZZ7
Potency order GDNF (GDNF, P39905) > neurturin (NRTN,
Q99748) > artemin (ARTN, Q5T4W7)
neurturin (NRTN, Q99748) > GDNF (GDNF, P39905) artemin (ARTN, Q5T4W7) persephin (PSPN,
O60542)
Labelled ligands [125I]GDNF (rat) (pKd 10.2–11.5) [92, 182] – – –
Comments: Inhibitors of other receptor tyrosine kinases, such as semaxanib, which inhibits VEGF receptor function, may also inhibit Ret function [131]. Mutations of RET and GDNF genes may be
involved in Hirschsprung’s disease, which is characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction.
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Integrins
Catalytic receptors! Integrins
Overview: Integrins are unusual signalling proteins that func-
tion to signal both from the extracellular environment into the
cell, but also from the cytoplasm to the external of the cell. The
intracellular signalling cascades associated with integrin activa-
tion focus on protein kinase activities, such as focal adhesion
kinase and Src. Based on this association between extracellular
signals and intracellular protein kinase activity, we have chosen
to include integrins in the ‘Catalytic receptors’ section of the
database until more stringent criteria from NC-IUPHAR allows
precise definition of their classification.
Integrins are heterodimeric entities, composed of α and β sub-
units, each 1TM proteins, which bind components of the extra-
cellular matrix or counter-receptors expressed on other cells. One
class of integrin contains an inserted domain (I) in its α subunit,
and if present (in α1, α2, α10, α11, αD, αE, αL, αM and αX), this
I domain contains the ligand binding site. All β subunits possess
a similar I-like domain, which has the capacity to bind ligand,
often recognising the RGD motif. The presence of an α subunit
I domain precludes ligand binding through the β subunit. Inte-
grins provide a link between ligand and the actin cytoskeleton
(through typically short intracellular domains). Integrins bind
several divalent cations, including a Mg2+ ion in the I or I-like
domain that is essential for ligand binding. Other cation bind-
ing sites may regulate integrin activity or stabilise the 3D struc-
ture. Integrins regulate the activity of particular protein kinases,
including focal adhesion kinase and integrin-linked kinase. Cel-
lular activation regulates integrin ligand affinity via inside-out
signalling and ligand binding to integrins can regulate cellular
activity via outside-in signalling.
Nomenclature integrin α1β1 integrin α2β1 integrin αIIbβ3 integrin α4β1
Subunits
integrin, beta 1 subunit
(fibronectin receptor, beta
polypeptide,
antigen CD29 includes MDF2,
MSK12),
integrin, alpha 1 subunit
integrin, beta 1 subunit
(fibronectin receptor, beta
polypeptide,
antigen CD29 includes MDF2,
MSK12),
integrin, alpha 2 subunit
(CD49B, alpha 2 subunit
of VLA-2 receptor)
integrin, beta 3 subunit
(platelet glycoprotein IIIa,
antigen CD61),
integrin, alpha IIb subunit
(platelet glycoprotein IIb of
IIb/IIIa complex, antigen CD41)
integrin, beta 1 subunit
(fibronectin receptor, beta
polypeptide,
antigen CD29 includes
MDF2, MSK12),
integrin, alpha 4 subunit
(antigen CD49D, alpha 4 subunit
of VLA-4 receptor)
Ligands collagen, laminin collagen, laminin,
thrombospondin
fibrinogen (FGA FGB FGG, P02671
P02675 P02679), fibronectin
(FN1, P02751),
von Willebrand factor (VWF,
P04275), vitronectin (VTN,
P04004), thrombospondin
fibronectin (FN1, P02751),
vascular cell adhesion protein 1
(VCAM1, P19320), osteopontin
(SPP1, P10451), thrombospondin
Inhibitors obtustatin (pIC50 9.1) [118] TCI15 (pIC50 7.9) [128] G4120 [124], GR 144053,
eptifibatide, tirofiban
BIO1211 (pIC50 8.3–9) [108],
TCS2314
Antibodies – – abciximab (Binding) [31] natalizumab (Inhibition) [1]
Comments – – – LDV-FITC is used as a probe at this
receptor.
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Nomenclature integrin α4β7 integrin α5β1 integrin α6β1 integrin α10β1
Subunits
integrin, alpha 4 subunit
(antigen CD49D, alpha 4 subunit
of
VLA-4 receptor),
integrin, beta 7 subunit
integrin, beta 1 subunit
(fibronectin receptor, beta
polypeptide, antigen CD29
includes MDF2, MSK12),
integrin, alpha 5 subunit
(fibronectin receptor, alpha
polypeptide)
integrin, beta 1 subunit
(fibronectin receptor, beta
polypeptide, antigen CD29
includes
MDF2, MSK12),
integrin, alpha 6 subunit
integrin, beta 1 subunit
(fibronectin receptor, beta
polypeptide, antigen CD29
includes MDF2, MSK12),
integrin, alpha 10 subunit
Ligands – fibronectin (FN1, P02751) laminin collagen
Antibodies vedolizumab (Antagonist) (pIC50
8.3) [151]
– – –
Nomenclature integrin α11β1 integrin αEβ7 integrin αLβ2 integrin αVβ3
Subunits
integrin, beta 1 subunit
(fibronectin receptor, beta polypeptide,
antigen CD29
includes MDF2, MSK12),
integrin, alpha 11 subunit
integrin, alpha E subunit
(antigen CD103, human mucosal
lymphocyte
antigen 1; alpha polypeptide),
integrin, beta 7 subunit
integrin, beta 2 subunit
(complement component 3 receptor 3
and 4 subunit),
integrin, alpha L subunit
(antigen CD11A (p180), lymphocyte
function-associated
antigen 1; alpha polypeptide)
integrin, beta 3 subunit
(platelet glycoprotein IIIa,
antigen CD61),
integrin, alpha V subunit
Ligands collagen E-cadherin ICAM-1 (ICAM1, P05362), ICAM-2 (ICAM2,
P13598)
vitronectin (VTN, P04004), fibronectin
(FN1, P02751), fibrinogen (FGA FGB
FGG, P02671 P02675 P02679),
osteopontin (SPP1, P10451),
von Willebrand factor (VWF, P04275),
thrombospondin, tenascin
Inhibitors – – A286982 (pIC50 7.4–7.5) [110] echistatin (pIC50 11.7) [101], P11
(pIC50 11.6) [101], cilengitide (pIC50
8.5) [61]
Antibodies – – – etaracizumab (Binding) (pKd 6.3) [201]
Comments: Integrin ligands
Collagen is the most abundant protein in metazoa, rich in
glycine and proline residues, made up of cross-linked triple heli-
cal structures, generated primarily by fibroblasts. Extensive post-
translational processing is conducted by prolyl and lysyl hydrox-
ylases, as well as transglutaminases. Over 40 genes for collagen-
α subunits have been identified in the human genome. The
collagen-binding integrins α1β1, α2β1, α10β1 and α11β1 recog-
nise a range of triple-helical peptidemotifs including GFOGER (O
= hydroxyproline), a synthetic peptide derived from the primary
sequence of collagen I (COL1A1 (COL1A1, P02452)) and collagen
II (COL2A1 (COL2A1, P02458)).
Laminin is an extracellular glycoprotein composed of α, β and
γ chains, for which five, four and three genes, respectively, are
identified in the human genome. It binds to α1β1, α2β1, α3,β1,
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α7β1 and α6β4 integrins10.
fibrinogen (FGA FGB FGG, P02671 P02675 P02679) is a
glycosylated hexamer composed of two α (FGA, P02671), two
β (FGB, P02675) and two γ (FGG, P02679,) subunits, linked by
disulphide bridges. It is found in plasma and alpha granules of
platelets. It forms cross-links between activated platelets medi-
ating aggregation by binding αIIbβ3; proteolysis by thrombin
cleaves short peptides termed fibrinopeptides to generate fibrin,
which polymerises as part of the blood coagulation cascade.
fibronectin (FN1, P02751) is a disulphide-linked homodimer
found as two major forms; a soluble dimeric form found in the
plasma and a tissue version that is polymeric, which is secreted
into the extracellular matrix by fibroblasts. Splice variation of the
gene product (FN1, P02751) generates multiple isoforms.
vitronectin (VTN, P04004) is a serum glycoprotein and extra-
cellular matrix protein which is found either as a monomer or,
following proteolysis, a disulphide -linked dimer.
osteopontin (SPP1, P10451) forms an integral part of the
mineralized matrix in bone, where it undergoes extensive post-
translation processing, including proteolysis and phosphoryla-
tion.
von Willebrand factor (VWF, P04275) is a glycoprotein
synthesised in vascular endothelial cells as a disulphide-linked
homodimer, but multimerises further in plasma and is deposited
on vessel wall collagen as a high molecular weight multimer. It is
responsible for capturing platelets under arterial shear flow (via
GPIb) and in thrombus propagation (via integrin αIIbβ3).
Subunits
Nomenclature integrin, alpha 1 subunit integrin, alpha 2 subunit
(CD49B, alpha 2 subunit of
VLA-2 receptor)
integrin, alpha IIb subunit
(platelet glycoprotein IIb
of IIb/IIIa complex,
antigen CD41)
integrin, alpha 3 subunit
(antigen CD49C, alpha 3
subunit of
VLA-3 receptor)
integrin, alpha 4 subunit
(antigen CD49D, alpha 4
subunit of
VLA-4 receptor)
integrin, alpha 5 subunit
(fibronectin receptor, alpha
polypeptide)
HGNC, UniProt ITGA1, P56199 ITGA2, P08514 ITGA2B, P17301 ITGA3, P26006 ITGA4, P13612 ITGA5, P08648
Antibodies – – – – natalizumab (Inhibition) [1] –
Nomenclature integrin, alpha 6
subunit
integrin, alpha 7
subunit
integrin, alpha 8
subunit
integrin, alpha 9
subunit
integrin, alpha
10 subunit
integrin, alpha
11 subunit
integrin, alpha D
subunit
HGNC, UniProt ITGA6, P23229 ITGA7, Q13683 ITGA8, P53708 ITGA9, Q13797 ITGA10, O75578 ITGA11,
Q9UKX5
ITGAD, Q13349
Nomenclature integrin, alpha E
subunit
(antigen CD103,
human mucosal
lymphocyte
antigen 1; alpha
polypeptide)
integrin, alpha L
subunit
(antigen CD11A
(p180), lymphocyte
function-associated
antigen 1; alpha
polypeptide)
integrin, alpha M
subunit
(complement
component 3
receptor 3 subunit)
integrin, alpha V
subunit
integrin, alpha X
subunit (complement
component 3
receptor 4 subunit)
integrin, beta 1 subunit (fibronectin receptor, beta
polypeptide, antigen
CD29 includes MDF2, MSK12)
HGNC, UniProt ITGAE, P38570 ITGAL, P20701 ITGAM, P11215 ITGAV, P06756 ITGAX, P20702 ITGB1, P05556
Antibodies – efalizumab (Binding)
(pKd 11.4) [81]
– – – –
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Nomenclature integrin, beta 2 subunit
(complement component 3
receptor 3 and 4 subunit)
integrin, beta 3 subunit
(platelet glycoprotein IIIa,
antigen CD61)
integrin, beta 4
subunit
integrin, beta 5
subunit
integrin, beta 6
subunit
integrin, beta 7
subunit
integrin, beta 8
subunit
HGNC, UniProt ITGB2, P05107 ITGB3, P05106 ITGB4, P16144 ITGB5, P18084 ITGB6, P18564 ITGB7, P26010 ITGB8, P26012
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Natriuretic peptide receptor family
Catalytic receptors! Natriuretic peptide receptor family
Overview: Natriuretic peptide receptors (provisional nomen-
clature) are a family of homodimeric, catalytic receptors with
a single TM domain and guanylyl cyclase (EC 4.6.1.2) activity
on the intracellular domain of the protein sequence. Isoforms
are activated by the peptide hormones atrial natriuretic peptide
(NPPA, P01160), brain natriuretic peptide (NPPB, P16860) and
C-type natriuretic peptide (NPPC, P23582). Another family
member is GC-C, the receptor for guanylin (GUCA2A, Q02747)
and uroguanylin (GUCA2B, Q16661) . Familymembers have con-
served ligand-binding, catalytic (guanylyl cyclase) and regulatory
domains with the exception of NPR-C which has an extracellu-
lar binding domain homologous to that of other NPRs, but with
a truncated intracellular domain which appears to couple, via
the Gi/o family of G-proteins, to activation of phospholipase C,
inwardly-rectifying potassium channels and inhibition of adeny-
lyl cyclase activity [136].
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Nomenclature guanylate cyclase 2C NPR-A NPR-B NPR-C
HGNC, UniProt GUCY2C, P25092 NPR1, P16066 NPR2, P20594 NPR3, P17342
Potency order uroguanylin (GUCA2B, Q16661) >
guanylin (GUCA2A, Q02747)
atrial natriuretic peptide (NPPA,
P01160) 
brain natriuretic peptide (NPPB,
P16860)
C-type natriuretic peptide (NPPC,
P23582) [173]
C-type natriuretic peptide (NPPC,
P23582)
atrial natriuretic peptide (NPPA,
P01160)
brain natriuretic peptide (NPPB,
P16860) [173]
atrial natriuretic peptide (NPPA,
P01160) >
C-type natriuretic peptide (NPPC,
P23582) 
brain natriuretic peptide (NPPB,
P16860) [173]
Endogenous agonists – atrial natriuretic peptide (NPPA,
P01160) (Selective) [144],
brain natriuretic peptide (NPPB,
P16860) (Selective) [144]
C-type natriuretic peptide (NPPC,
P23582) (Selective) [173]
osteocrin (OSTN, P61366)
(Selective) [129]
Selective agonists linaclotide (pKi 8.9) [20, 67],
E. coli heat-stable enterotoxin (STa)
(pKi 8.8) [20]
sANP [144] – cANF4-23 [114]
Selective antagonists – A-71915 (pKi 9.2–9.5) [41],
[Asu7,23’]β-ANP-(7-28) (pKi 7.5)
[83], anantin [202]
[Ser11](N-CNP,C-ANP)pBNP2-15
[42]
AP811 (pKi 9.3) [185], M372049
[75]
Labelled ligands [125I]Sta (Agonist) (pKd 7.8) [66] [
125I]ANP (human) (Agonist) [125I]CNP (human) [125I]ANP (human)
Comments: The polysaccharide obtained from fermentation of
Aureobasidium species, HS142-1, acts as an antagonist at both
NPR-A and NPR-B receptors [132].
GUCY2D (RetGC1, GC-E, Q02846) and GUCY2F (RetGC2, GC-
F, P51841) are predominantly retinal guanylyl cyclase activities,
which are inhibited by calcium ions acting through the guany-
lyl cyclase activating peptides GCAP1 (GUCA1A, 43080), GCAP2
(GUCA1B, Q9UMX6) and GCAP3 (GUCA1C, O95843) [78].
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Pattern recognition receptors
Catalytic receptors! Pattern recognition receptors
Overview: Pattern Recognition Receptors (PRRs, [174])
(nomenclature as agreed by NC-IUPHAR sub-committee
on Pattern Recognition Receptors, [18]) participate in
the innate immune response to microbial agents, the stimu-
lation of which leads to activation of intracellular enzymes
and regulation of gene transcription. PRRs include both cell-
surface and intracellular proteins, including toll-like receptors
(TLRs), nucleotide-binding oligomerization domain-like recep-
tors (NLRs, also known as NOD-like receptors) and the mannose
receptor family (ENSFM00250000004089). PRRs may be divided
into signalling-associated members, identified here, and en-
docytic members (such as the mannose receptor family), the
function of which appears to be to recognise particular micro-
bial motifs for subsequent cell attachment, internalisation and
destruction.
PRRs express multiple leucine-rich regions to bind a range
of microbially-derived ligands, termed PAMPs or pathogen-
associated molecular patterns, which includes peptides, carbo-
hydrates, peptidoglycans, lipoproteins, lipopolysaccharides, and
nucleic acids.
Further Reading
Bryant CE et al. (2015) International Union of Basic and Clinical Pharmacology. XCVI. Pattern
recognition receptors in health and disease. Pharmacol. Rev. 67: 462-504 [PMID:25829385]
Davis BK et al. (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases.
Annu. Rev. Immunol. 29: 707-35 [PMID:21219188]
Ting JP et al. (2008) The NLR gene family: a standard nomenclature. Immunity 28: 285-7
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Toll-like receptor family
Catalytic receptors! Pattern recognition receptors! Toll-like receptor family
Overview: Members of the toll-like family of receptors (nomen-
clature recommended by the NC-IUPHAR subcommittee on pat-
tern recognition receptors, [18]) share significant homology with
the interleukin-1 receptor family and appear to require dimer-
ization either as homo- or heterodimers for functional activity.
Heterodimerization appears to influence the potency of ligand
binding substantially (e.g. TLR1/2 and TLR2/6, [175, 176]). TLR1,
TLR2, TLR4, TLR5, TLR6 and TLR11 are cell-surface proteins,
while other members are associated with intracellular organelles,
signalling through theMyD88-dependent pathways (with the ex-
ception of TLR3). As well as responding to exogenous infectious
agents, it has been suggested that selected members of the family
may be activated by endogenous ligands, such as hsp60 (HSPD1,
P10809) [141].
Nomenclature TLR1 TLR2 TLR3 TLR4 TLR5
HGNC, UniProt TLR1, Q15399 TLR2, O60603 TLR3, O15455 TLR4, O00206 TLR5, O60602
Agonists – peptidoglycan [165, 205] polyIC [6] LPS [150], paclitaxel [85] flagellin [69]
Comments Functions as a heterodimer with
TLR2 in detection of triacylated
lipoproteins. Activated by the
synthetic analogue Pam3CSK4.
Functions as a heterodimer with either
TLR1 or TLR6 in the detection of
triacylated and diacylated lipopeptides
respectively. TLR1/2 and 2/6
heterodimers can be activated by the
synthetic lipopeptides Pam3CSK4 and
Pam2CSK4 respectively. There is some
debate in the field as to whether or not
peptidoglycan is a direct agonist of TLR2,
or whether the early studies reporting this
contained contaminating lipoproteins.
Involved in endosomal detection
of dsRNA; pro-inflammatory.
eritoran (E5564) is a lipid A
analogue, which has been
described as a TLR4 antagonist
[80]. TLR4 signals in conjunction
with the co-factor MD2.
Involved in the detection
of bacterial flagellin;
pro-inflammatory.
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Nomenclature TLR6 TLR7 TLR8 TLR9 TLR10 TLR11
HGNC, UniProt TLR6, Q9Y2C9 TLR7, Q9NYK1 TLR8, Q9NR97 TLR9, Q9NR96 TLR10, Q9BXR5 –
Agonists – imiquimod [72],
loxoribine [70],
resiquimod [72]
imiquimod,
resiquimod [72]
– – –
Antagonists –
hydroxychloroquine
(pIC50 5.6) [98]
–
hydroxychloroquine
(pIC50 7.1) [98]
– –
Comments Functions as a
heterodimer with
TLR2. Involved in
the pro-
inflammatory
response to
diacylated
bacterial
lipopeptides.
Activated by
imidazoquinoline
derivatives and
RNA oligoribonu-
cleotides.
Involved in
endosomal
detection of
ssRNA; pro-
inflammatory.
Activated by
imidazoquinoline
derivatives and
RNA oligoribonu-
cleotides.
Endosomal
detection of
ssRNA; pro-
inflammatory.
Toll-like receptor
9 interacts with
unmethylated
CpG
dinucleotides
from bacterial
DNA [73].
Activated by
CpG rich DNA
sequences; pro-
inflammatory.
Murine TLR10
has a retroviral
insertion that
makes in
non-functional.
Found in mouse
Further Reading
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NOD-like receptor family
Catalytic receptors! Pattern recognition receptors! NOD-like receptor family
Overview: The nucleotide-binding oligomerization domain,
leucine-rich repeat (NLR) family of receptors (nomenclature rec-
ommended by the NC-IUPHAR subcommittee on pattern recog-
nition receptors [18]) share a common domain organisation. This
consists of an N-terminal effector domain, a central nucleotide-
binding and oligomerization domain (NOD; also referred to as
a NACHT domain), and C-terminal leucine-rich repeats (LRR)
which have regulatory and ligand recognition functions. The
type of effector domain has resulted in the division of NLR fam-
ily members into two major sub-families, NLRC and NLRP, along
with three smaller sub-families NLRA, NLRB and NLRX [178].
NLRC members express an N-terminal caspase recruitment do-
main (CARD) and NLRP members an N-terminal Pyrin domain
(PYD).
Upon activation the NLRC family members NOD1 (NLRC1) and
NOD2 (NLRC2) recruit a serine/threonine kinase RIPK2 (recep-
tor interacting serine/threonine kinase 2, O43353, also known
as CARD3, CARDIAK, RICK, RIP2) leading to signalling through
NFB and MAP kinase. Activation of NLRC4 (previously known
as IPAF) and members of the NLRP3 family, including NLRP1
and NLRP3, leads to formation of a large multiprotein complex
known as the inflammasome. In addition to NLR proteins other
key members of the inflammasome include the adaptor protein
ASC (apoptosis-associated speck-like protein containing a CARD,
also known as PYCARD, CARD5, TMS1, Q9ULZ3) and inflamma-
tory caspases. The inflammasome activates the pro-inflammatory
cytokines IL-1β (IL1B, P01584) and IL-18 (IL18, Q14116) [18, 37].
Searchable database: http://www.guidetopharmacology.org/index.jsp NOD-like receptor family 5997
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13353/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. British Journal of Pharmacology (2015) 172, 5979–6023
Nomenclature nucleotide-binding oligomerization
domain containing 1
nucleotide-binding oligomerization
domain containing 2
NLRC3 NLRC4 NLRC5
Common abreviation NOD1 NOD2 – – –
HGNC, UniProt NOD1, Q9Y239 NOD2, Q9HC29 NLRC3, Q7RTR2 NLRC4, Q9NPP4 NLRC5, Q86WI3
Agonists meso-DAP muramyl dipeptide – – –
Comments – NOD2 has also been reported to be
activated by ssRNA [160] although this has
not been widely reproduced.
– NLRC4 forms an inflammasome in
conjunction with the NAIP
proteins and responds to bacterial
flagellin and type III secretion
system rod proteins.
–
Nomenclature NLRX1 CIITA NLRP1 NLRP2
HGNC, UniProt NLRX1, Q86UT6 CIITA, P33076 NLRP1, Q9C000 NLRP2, Q9NX02
Agonists – – muramyl dipeptide –
Comments – – NLRP1 has 3 murine orthologues which lack the N-terminal Pyrin
domain. Murine NLRP1b (ENSMUSG00000070390) is the best
characterised, responding to Anthrax Lethal Toxin.
Along with NLRP7, NLRP2 is the product of a primate-specific gene
duplication.
Nomenclature NLRP3 NLRP4 NLRP5 NLRP6
HGNC, UniProt NLRP3, Q96P20 NLRP4, Q96MN2 NLRP5, P59047 NLRP6, P59044
Inhibitors MCC950 (pIC50 >8) [30] – – –
Comments Multiple virus particles have been shown to act as agonists, including Sendai and
influenza. NLRP3 has been shown to be activated following disruption of cellular
haemostasis by a wide-variety of exogenous and endogenous molecules. The identity
of the precise agonist that interacts with NLRP3 remains enigmatic.
Expanded in the mouse resulting in 7 orthologues. – –
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Nomenclature NLRP7 NLRP8 NLRP9 NLRP10
HGNC, UniProt NLRP7, Q8WX94 NLRP8, Q86W28 NLRP9, Q7RTR0 NLRP10, Q86W26
Comments Absent in mouse. Along with NLRP2 the product of a primate-specific gene
duplication.
Absent in mouse This receptor has three murine orthologues. –
Nomenclature NLRP11 NLRP12 NLRP13 NLRP14
HGNC, UniProt NLRP11, P59045 NLRP12, P59046 NLRP13, Q86W25 NLRP14, Q86W24
Comments Absent in mouse – Absent in mouse –
Comments: NLRP3 has also been reported to respond to host-
derived products, known as danger-associated molecular pat-
terns, or DAMPs, including uric acid [122], ATP, L-glucose,
hyaluronan and amyloid β (APP, P05067) [163].
Loss-of-function mutations of NLRP3 are associated with cold au-
toinflammatory and Muckle-Wells syndromes.
This family also includes NLR family, apoptosis inhibitory protein
(NAIP, Q13075) which can be found in the ’Inhibitors of apop-
tosis (IAP) protein family’ in the Other protein targets section of
the Guide.
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Receptor serine/threonine kinase (RSTK) family
Catalytic receptors! Receptor kinases! TKL: Tyrosine kinase-like! Receptor serine/threonine kinase (RSTK) family
Overview: Receptor serine/threonine kinases (RTSK),
EC 2.7.11.30, respond to particular cytokines, the transforming
growth factor β (TGFβ) and bone morphogenetic protein (BMP)
families, and may be divided into two subfamilies on the basis of
structural similarities. Agonist binding initiates formation of a
cell-surface complex of type I and type II RSTK, possibly heterote-
trameric, where where both subunits express serine/threonine
kinase activity. The type I receptor serine/threonine kinases are
also known as activin receptors or activin receptor-like kinases,
ALKs, for which a systematic nomenclature has been proposed
(ALK1-7). The type II protein phosphorylates the kinase domain
of the type I partner (sometimes referred to as the signal prop-
agating subunit), causing displacement of the protein partners,
such as the FKBP12 FK506-binding protein FKBP1A (P62942) and
allowing the binding and phosphorylation of particular mem-
bers of the Smad family. These migrate to the nucleus and act
as complexes to regulate gene transcription. Type III receptors,
sometimes called co-receptors or accessory proteins, regulate
the signalling of the receptor complex, in either enhancing (for
example, presenting the ligand to the receptor) or inhibitory
manners. TGFβ family ligand signalling may be inhibited by
endogenous proteins, such as follistatin (FST, P19883), which
binds and neutralizes activins to prevent activation of the target
receptors.
Endogenous agonists, approximately 30 in man, are often de-
scribed as paracrine messengers acting close to the source of
production. They are characterized by six conserved cys-
teine residues and are divided into two subfamilies on the
basis of sequence comparison and signalling pathways acti-
vated, the TGFβ/activin/nodal subfamily and the BMP/GDF
(growth/differentiation factor)/MIS (Müllerian inhibiting sub-
stance) subfamily. Ligands active at RSTKs appear to be generated
as large precursors which undergo complex maturation processes
[105]. Some are known to form disulphide-linked homo- and/or
heterodimeric complexes. Thus, inhibins are α subunits linked
to a variety of β chains, while activins are combinations of β sub-
units.
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Comments: A number of endogenous inhibitory ligands have been identified for RSTKs, including BMP-3 (BMP3, P12645), inhibin α (INHA, P05111), inhibin βC (INHBC, P55103) and inhibin βE (INHBE,
P58166).
An appraisal of small molecule inhibitors of TGFβ and BMP signalling concluded that TGFβ pathway inhibitors were more selective than BMP signalling inhibitors [186]. The authors confirmed the
selectivity of TGF-beta RI inhibitor III to inhibit TGFβ signalling through ALK4, ALK5, ALK7 [36]. Dorsomorphin inhibits BMP signalling through ALK2 and ALK3, it also inhibits AMP kinase [209].
Smads were identified as mammalian orthologues of Drosophila genes termed “mothers against decapentaplegic” and may be divided into Receptor-regulated Smads (R-Smads, including Smad1, Smad2,
Smad3, Smad5 and Smad8), Co-mediated Smad (Co-Smad, Smad4) and Inhibitory Smads (I-Smad, Smad6 and Smad7). R-Smads form heteromeric complexes with Co-Smad. I-Smads compete for binding
of R-Smad with both receptors and Co-Smad.
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Type I receptor serine/threonine kinases
Catalytic receptors! Receptor kinases! TKL: Tyrosine kinase-like! Receptor serine/threonine kinase (RSTK) family! Type I receptor serine/threonine kinases
Overview: The type I receptor serine/threonine kinases are also known as activin receptors or activin receptor-like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1-7).
Nomenclature activin A receptor type II-like 1 activin A receptor, type I bone morphogenetic protein receptor, type IA activin A receptor, type IB
Common
abreviation
ALK1 ALK2 BMPR1A ALK4
HGNC, UniProt ACVRL1, P37023 ACVR1, Q04771 BMPR1A, P36894 ACVR1B, P36896
EC number 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30
Inhibitors compound 13d [PMID: 23639540] (pIC50 >8.3)
[45], compound 13r [PMID: 23639540] (pIC50
>8.3) [45]
compound 13d [PMID: 23639540] (pIC50 >8.3)
[45], ML347 (pIC50 7.5) [45]
compound 13d [PMID: 23639540] (pIC50 >8.3)
[45]
–
Selective
inhibitors
– – – EW-7197 (pIC50 7.9) [82]
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Nomenclature transforming growth factor, beta receptor 1
bone morphogenetic protein receptor, type IB
activin A receptor, type IC
Common abreviation TGFBR1 BMPR1B ALK7
HGNC, UniProt TGFBR1, P36897 BMPR1B, O00238 ACVR1C, Q8NER5
EC number 2.7.11.30 2.7.11.30 2.7.11.30
Inhibitors LY2109761 (pKi 7.4) [125],
compound 15b [PMID: 16539403] (pIC50
7.1) [104]
compound 13d [PMID: 23639540] (pIC50
>8.3) [45]
–
Selective inhibitors EW-7197 (pIC50 8) [82] – –
Type II receptor serine/threonine kinases
Catalytic receptors! Receptor kinases! TKL: Tyrosine kinase-like! Receptor serine/threonine kinase (RSTK) family! Type II receptor serine/threonine kinases
Nomenclature activin A receptor, type IIA activin A receptor, type IIB anti-Mullerian hormone receptor,
type II
bone morphogenetic protein
receptor, type II
(serine/threonine kinase)
transforming growth factor, beta
receptor II (70/80kDa)
Common
abreviation
ActR2 ActR2B MISR2 BMPR2 TGFBR2
HGNC, UniProt ACVR2A, P27037 ACVR2B, Q13705 AMHR2, Q16671 BMPR2, Q13873 TGFBR2, P37173
EC number 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30
Inhibitors – – – – compound 13d [PMID: 23639540] (pIC50
7.6) [45]
Antibodies – bimagrumab (Binding) (pKd 11.8)
[12]
– – –
Type III receptor serine/threonine kinases
Catalytic receptors! Receptor kinases! TKL: Tyrosine kinase-like! Receptor serine/threonine kinase (RSTK) family! Type III receptor serine/threonine kinases
Nomenclature transforming growth factor, beta receptor III
Common abreviation TGFBR3
HGNC, UniProt TGFBR3, Q03167
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RSTK functional heteromers
Catalytic receptors! Receptor kinases! TKL: Tyrosine kinase-like! Receptor serine/threonine kinase (RSTK) family! RSTK functional heteromers
Overview: For the receptors listed on this page, the exact combination of subunits forming the functional heteromeric receptors is unknown.
Nomenclature Transforming growth
factor β receptor
Bone morphogenetic protein
receptors
Growth/differentiation factor
receptors
Activin receptors Anti-Müllerian
hormone receptors
Subunits transforming growth factor,
beta receptor 1
(Type I),
transforming growth factor,
beta receptor III
(Type III),
transforming growth factor,
beta receptor II (70/80kDa)
(Type II)
bone morphogenetic protein
receptor, type IB
(Type I), activin A receptor, type IIB
(Type II),
activin A receptor,
type IIA
(Type II),
activin A receptor type
II-like 1
(Type I),
activin A receptor,
type I
(Type I),
bone morphogenetic protein
receptor, type IA
(Type I),
bone morphogenetic protein
receptor, type II (serine/threonine
kinase)
(Type II)
transforming growth factor,
beta receptor 1
(Type I),
bone morphogenetic protein receptor,
type IB
(Type I),
activin A receptor,
type IIB
(Type II), activin A receptor, type IIA
(Type II),
activin A receptor,
type IC
(Type I),
bone morphogenetic protein
receptor, type IA
(Type I),
activin A receptor,
type IB
(Type I),
bone morphogenetic protein receptor,
type II (serine/threonine kinase)
(Type II)
activin A receptor,
type IIB
(Type II),
activin A receptor,
type IIA
(Type II),
activin A receptor,
type IC
(Type I),
activin A receptor,
type IB
(Type I)
anti-Mullerian hormone
receptor, type II
(Type II),
bone morphogenetic protein
receptor, type IB
(Type I),
activin A receptor,
type I
(Type I),
bone morphogenetic protein
receptor, type IA
(Type I)
Coupling Smad2, Smad3 [134, 167] Smad1, Smad5, Smad8 [134, 167] Smad1, Smad5, Smad8 [134, 167] Smad2, Smad3 [167] Smad1, Smad5, Smad8
[134, 167]
Endogenous
agonists
TGFβ1 (TGFB1, P01137),
TGFβ2
(TGFB2, P61812), TGFβ3
(TGFB3, P10600)
BMP-10 (BMP10, O95393), BMP-2
(BMP2, P12643), BMP-4 (BMP4,
P12644), BMP-5 (BMP5, P22003),
BMP-6 (BMP6, P22004), BMP-7 (BMP7,
P18075), BMP-8A (BMP8A, Q7Z5Y6),
BMP-8B (BMP8B, P34820), BMP-9
(GDF2, Q9UK05)
growth/differentiation factor-1 (GDF1,
P27539),
growth/differentiation factor-10 (GDF10,
P55107), growth/differentiation factor-3
(GDF3, Q9NR23),
growth/differentiation factor-7 (GDF7,
Q7Z4P5), growth/differentiation factor-9
(GDF9, O60383)
activin A (INHBA, P08476), activin AB
(INHBA INHBB, P08476 P09529),
activin B (INHBB, P09529), inhibin A
(INHA INHBA, P05111 P08476)
Müllerian inhibiting substance
(AMH, P03971)
Comments – – – Activin receptors are heteromeric
complexes comprising activin receptor
type I and type II subunits.
–
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Receptor tyrosine kinases
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases
Overview: Receptor tyrosine kinases (RTKs), a family of cell-
surface receptors, which transduce signals to polypeptide and
protein hormones, cytokines and growth factors are key regula-
tors of critical cellular processes, such as proliferation and differ-
entiation, cell survival and metabolism, cell migration and cell
cycle control [14, 62, 184]. In the human genome, 58 RTKs have
been identified, which fall into 20 families [102].
All RTKs display an extracellular ligand binding domain, a sin-
gle transmembrane helix, a cytoplasmic region containing the
protein tyrosine kinase activity (occasionally split into two do-
mains by an insertion, termed the kinase insertion), with juxta-
membrane and C-terminal regulatory regions. Agonist binding
to the extracellular domain evokes dimerization, and sometimes
oligomerization, of RTKs (a small subset of RTKs forms multi-
mers even in the absence of activating ligand). This leads to au-
tophosphorylation in the tyrosine kinase domain in a trans ori-
entation, serving as a site of assembly of protein complexes and
stimulation of multiple signal transduction pathways, including
phospholipase C-γ, mitogen-activated protein kinases and phos-
phatidylinositol 3-kinase [184].
RTKs are of widespread interest not only through physiological
functions, but also as drug targets in many types of cancer and
other disease states. Many diseases result from genetic changes
or abnormalities that either alter the activity, abundance, cellu-
lar distribution and/or regulation of RTKs. Therefore, drugs that
modify the dysregulated functions of these RTKs have been de-
veloped which fall into two categories. One group is often de-
scribed as ‘biologicals’, which block the activation of RTKs di-
rectly or by chelating the cognate ligands, while the second are
small molecules designed to inhibit the tyrosine kinase activity
directly.
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Type I RTKs: ErbB (epidermal growth factor) receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type I RTKs: ErbB (epidermal growth factor) receptor family
Overview: ErbB family receptors are Class I receptor tyrosine ki-
nases [62]. ERBB2 (also known as HER-2 or NEU) appears to act as
an essential partner for the other members of the family without
itself being activated by a cognate ligand [63]. Ligands of the ErbB
family of receptors are peptides, many of which are generated by
proteolytic cleavage of cell-surface proteins. HER/ErbB is the vi-
ral counterpart to the receptor tyrosine kinase EGFR. All family
members heterodimerize with each other to activate downstream
signalling pathways and are aberrantly expressed in many can-
cers, particularly forms of breast cancer.
Nomenclature epidermal growth factor receptor erb-b2 receptor tyrosine kinase 2 erb-b2 receptor tyrosine kinase 3 erb-b2 receptor tyrosine kinase 4
Common abreviation EGFR HER2 HER3 HER4
HGNC, UniProt EGFR, P00533 ERBB2, P04626 ERBB3, P21860 ERBB4, Q15303
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands EGF (EGF, P01133) (Binding), HB-EGF (HBEGF,
Q99075) (Binding), TGFα (TGFA, P01135) (Binding),
amphiregulin (AREG, P15514) (Binding), betacellulin
(BTC, P35070) (Binding), epigen (EPGN, Q6UW88)
(Binding), epiregulin (EREG, O14944) (Binding)
– neuregulin-1 (NRG1, Q02297),
neuregulin-2 (NRG2, O14511)
HB-EGF (HBEGF, Q99075), betacellulin
(BTC, P35070), epiregulin (EREG, O14944),
neuregulin-1 (NRG1, Q02297),
neuregulin-2 (NRG2, O14511),
neuregulin-3 (NRG3, P56975),
neuregulin-4 (NRG4, Q8WWG1)
Inhibitors canertinib (pKd 9.7) [38], afatinib (pKd 9.6) [38],
XL-647 (pIC50 9.5) [57], afatinib (pIC50 8–9.3) [33,
103], erlotinib (pKd 9.2) [38], erlotinib (pIC50 9)
[207], gefitinib (pKd 9) [38], canertinib (pIC50 8.8)
[170], BMS-690514 (pIC50 8.3) [117], gefitinib (pKi
8.3) [197], AG1478 (pIC50 8.2) [181], poziotinib
(pIC50 8.1) [140], lapatinib (pIC50 8) [159],
EGFR/ErbB-2 inhibitor (pIC50 7.7) [28], AG 112
(pIC50 6.9) [56], rociletinib (pKi 6.5) [187], AG 490
(pIC50 6.4) [55]
poziotinib (pIC50 8.3) [140], neratinib
(pKd 8.2) [38], lapatinib (pKd 8.1) [38],
lapatinib (pIC50 8) [159], CP-724714
(pIC50 7.9) [65], XL-647 (pIC50 7.8) [57],
BMS-690514 (pIC50 7.7) [117], neratinib
(pIC50 7.2) [155], EGFR/ErbB-2 inhibitor
(pIC50 7.1) [28]
– poziotinib (pIC50 7.6) [140]
Antibodies necitumumab (Binding) (pKd 9.5) [111], cetuximab
(Binding) (pKd 9.4) [60], panitumumab (Inhibition)
pertuzumab (Inhibition) (pIC50 >8) [84],
trastuzumab (Inhibition)
– –
Comments: [125I]EGF (human) has been used to label the ErbB1 EGF receptor. The extracellular domain of ErbB2 can be targetted by the antibodies trastuzumab and pertuzumab to inhibit ErbB family
action. The intracellular ATP-binding site of the tyrosine kinase domain can be inhibited by GW583340 (7.9-8.0, [54]), gefitinib, erlotinib and tyrphostins AG879 and AG1478.
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Type II RTKs: Insulin receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type II RTKs: Insulin receptor family
Overview: The circulating peptide hormones insulin (INS,
P01308) and the related insulin-like growth factors (IGF) activate
Class II receptor tyrosine kinases [62], to evoke cellular responses,
mediated throughmultiple intracellular adaptor proteins. Excep-
tionally amongst the catalytic receptors, the functional receptor
in the insulin receptor family is derived from a single gene prod-
uct, cleaved post-translationally into two peptides, which then
cross-link via disulphide bridges to form a heterotetramer. In-
triguingly, the endogenous peptide ligands are formed in a par-
allel fashion with post-translational processing producing a het-
erodimer linked by disulphide bridges. Signalling through the re-
ceptors is mediated through a rapid autophosphorylation event
at intracellular tyrosine residues, followed by recruitment of mul-
tiple adaptor proteins, notably IRS1 (P35568), IRS2 (Q9Y4H2),
SHC1 (P29353), GRB2 (P62993) and SOS1 (Q07889).
Serum levels of free IGFs are kept low by the action of IGF binding
proteins (IGFBP1-5, P08833, P18065, P17936, P22692, P24593),
which sequester the IGFs; overexpression of IGFBPs may induce
apoptosis, while IGFBP levels are also altered in some cancers.
Nomenclature Insulin receptor Insulin-like growth factor I receptor Insulin receptor-related receptor
Common abreviation InsR IGF1R IRR
HGNC, UniProt INSR, P06213 IGF1R, P08069 INSRR, P14616
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Inhibitors – BMS-754807 (pIC50 8.7) [199], GSK-1838705A
(pIC50 8.7) [161], GSK-1838705A (pKd 8.1) [38],
PQ401 (pIC50 >6) [50], AG 1024 (pIC50 4.7) [153]
–
Selective inhibitors – NVP-AEW541 (pIC50 9.4) [53] –
Endogenous agonists insulin (INS, P01308) insulin-like growth factor 1 (IGF1, P05019),
insulin-like growth factor 2 (IGF2, P01344)
–
Comments: There is evidence for low potency binding and ac-
tivation of insulin receptors by IGF1. IGF2 also binds and ac-
tivates the cation-independent mannose 6-phosphate receptor
(also known as the insulin-like growth factor II receptor), which
lacks classical signalling capacity and appears to subserve a traf-
ficking role [115]. INSRR, which has a much more discrete local-
ization, being predominant in the kidney [95], currently lacks a
cognate ligand or evidence for functional impact.
Antibodies targetting IGF1, IGF2 and the extracellular portion of
the IGF1 receptor are in clinical trials.
PQ401 inhibits the insulin-like growth factor receptor [5], while
BMS-536924 inhibits both the insulin receptor and the insulin-
like growth factor receptor [198].
Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
Overview: Type III RTKs include PDGFR, CSF-1R (Ems), Kit and FLT3, which function as homo- or heterodimers. Endogenous ligands of PDGF receptors are homo- or heterodimeric: PDGFA, PDGFB,
VEGFE and PDGFD (PDGFD, Q9GZP0) combine as homo- or heterodimers to activate homo- or heterodimeric PDGF receptors. SCF is a dimeric ligand for KIT. Ligands for CSF1R are either monomeric or
dimeric glycoproteins, while the endogenous agonist for FLT3 is a homodimer.
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Nomenclature platelet-derived growth
factor receptor, alpha polypeptide
platelet-derived growth
factor receptor, beta polypeptide
v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog
colony stimulating
factor 1 receptor
fms-related tyrosine kinase 3
Common
abreviation
PDGFRα PDGFRβ Kit CSFR FLT3
HGNC, UniProt PDGFRA, P16234 PDGFRB, P09619 KIT, P10721 CSF1R, P07333 FLT3, P36888
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous
ligands
PDGF PDGF – – –
Endogenous
ligands
– – stem cell factor (KITLG, P21583) G-CSF (CSF3, P09919), GM-CSF
(CSF2, P04141), M-CSF (CSF1,
P09603)
Fms-related tyrosine kinase 3 ligand
(FLT3LG, P49771)
Inhibitors PP121 (pIC50 8.7) [7], crenolanib
(pKd 8.7) [71], ENMD-2076
(pIC50 7.2) [149]
crenolanib (pKd 8.5) [71],
SU-14813 (pIC50 8.4) [147],
famitinib (pIC50 8.4) [24],
sunitinib (pIC50 8.2) [91],
sunitinib (pKi 8.1) [126]
sunitinib (pKd 9.4) [38], famitinib
(pIC50 8.7) [24], masitinib (pKd
8.1) [38], SU-14813 (pIC50 7.8)
[147], AKN-028 (pIC50 7.5) [46],
sorafenib (pIC50 7.2) [196]
JNJ-28312141 (pIC50 9.2) [116],
Ki-20227 (pKd 9.1) [38],
Ki-20227 (pIC50 8.7) [143],
GW-2580 (pKd 8.7) [38],
JNJ-28312141 (pKd 8.5) [38]
AC710 (pKd 9.3) [109], linifanib
(pKd 9.2) [38], dovitinib (pKd 9.2)
[38], crenolanib (pKd 9.1) [71],
AST-487 (pKd 9.1) [38],
compound 8h [PMID: 22765894]
(pIC50 9.1) [88], dovitinib (pIC50
8.5–9) [157, 183], ENMD-2076
(pIC50 8.5) [149], tandutinib (pKd
8.5) [38], quizartinib (pIC50 8.4)
[206], AKN-028 (pIC50 8.2) [46],
KW-2449 (pIC50 8.2) [168],
lestaurtinib (pKd 8.1) [38],
midostaurin (pKd 8) [38], KW-2449
(pKd 7.8) [38], sorafenib (pIC50 7.2)
[196], AST-487 (pKi 6.9) [193],
tandutinib (pIC50 6.7) [86], AST-487
(pIC50 6.3) [2], midostaurin (pIC50
6.3) [192]
Selective
inhibitors
CP-673451 (pIC50 8) [158] CP-673451 (pIC50 9) [158] – GW-2580 (pIC50 7.2) [32] G749 (pIC50 9.4) [99]
Comments – – – – 5’-fluoroindirubinoxime has been
described as a selective FLT3
inhibitor [25].
Comments: Various small molecular inhibitors of type III RTKs have been described, including imatinib and nilotinib (targetting PDGFR, KIT and CSF1R); midostaurin and AC220 (quizartinib; FLT3), as
well as pan-type III RTK inhibitors such as sunitinib and sorafenib [148]; 5’-fluoroindirubinoxime has been described as a selective FLT3 inhibitor [2].
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Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family
Overview: VEGF receptors are homo- and heterodimeric pro-
teins, which are characterized by seven Ig-like loops in their ex-
tracellular domains and a split kinase domain in the cytoplasmic
region. They are key regulators of angiogenesis and lymphan-
giogenesis; as such, they have been the focus of drug discov-
ery for conditions such as metastatic cancer. Splice variants of
VEGFR1 and VEGFR2 generate truncated proteins limited to the
extracellular domains, capable of homodimerisation and bind-
ing VEGF ligands as a soluble, non-signalling entity. Ligands
at VEGF receptors are typically homodimeric. VEGFA (VEGFA,
P15692) is able to activate VEGFR1 homodimers, VEGFR1/2 het-
erodimers and VEGFR2/3 heterodimers. VEGFB (VEGFB, P49765)
and placental growth factor (PGF, P49763) activate VEGFR1 ho-
modimers, while VEGFC (VEGFC, P49767) and VEGFD (FIGF,
O43915) activate VEGFR2/3 heterodimers and VEGFR3 homod-
imers, and, following proteolysis, VEGFR2 homodimers.
Nomenclature fms-related tyrosine kinase 1 kinase insert domain receptor fms-related tyrosine kinase 4
Common abreviation VEGFR-1 VEGFR-2 VEGFR-3
HGNC, UniProt FLT1, P17948 KDR, P35968 FLT4, P35916
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands VEGFA (VEGFA, P15692), VEGFB (VEGFB, P49765) VEGFA (VEGFA, P15692), VEGFC (VEGFC, P49767),
VEGFE (PDGFC, Q9NRA1)
VEGFC (VEGFC, P49767), VEGFD (FIGF, O43915),
VEGFE (PDGFC, Q9NRA1)
Inhibitors SU-14813 (pIC50 8.7) [147], CEP-11981 (pIC50
8.5) [77], semaxanib (pIC50 8.1) [15]
axitinib (pIC50 9.6) [100], cabozantinib (pIC50 9.5)
[203], foretinib (pIC50 8.2–9.1) [137], cediranib
(pKd 9) [38], XL-647 (pIC50 8.8) [57],
compound 13a [PMID: 23639540] (pIC50 8.8)
[45], SU-14813 (pKd 8.6) [38], motesanib (pKd
8.6) [38], famitinib (pIC50 8.3) [24], axitinib (pKd
8.2) [38], PLX-4720 (pKi 8.1) [126], CP-547632
(pIC50 8) [11], PP121 (pIC50 7.9) [7], golvatinib
(pIC50 7.8) [139], brivanib (pIC50 7.6) [13],
ENMD-2076 (pIC50 7.4) [149], BMS-690514
(pIC50 7.3) [117], SU-14813 (pIC50 7.3) [147],
sorafenib (pKd 7.2) [38], vatalanib (pKd 7.2) [38],
sorafenib (pIC50 7.1) [196]
XL-647 (pIC50 8.1) [57], sunitinib (pIC50 8.1) [87],
nintedanib (pIC50 7.9) [74]
(Sub)family-selective
inhibitors
pazopanib (pIC50 8) [68] pazopanib (pKd 7.8) [38], pazopanib (pIC50 7.5)
[68]
pazopanib (pIC50 7.3) [68]
Antibodies – ramucirumab (Antagonist) (pIC50 9) [113] –
Comments: The VEGFR, as well as VEGF ligands, have been targeted by antibodies and tyrosine kinase inhibitors. DMH4 [49], Ki8751 [94] and ZM323881, a novel inhibitor of vascular endothelial
growth factor-receptor-2 tyrosine kinase activity [195] are described as VEGFR2-selective tyrosine kinase inhibitors. Bevacizumab is a monoclonal antibody directed against VEGF-A, used clinically for the
treatment of certain metastatic cancers; an antibody fragment has been used for wet age-related macular degeneration.
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Type V RTKs: FGF (fibroblast growth factor) receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type V RTKs: FGF (fibroblast growth factor) receptor family
Overview: Fibroblast growth factor (FGF) family receptors act as
homo- and heterodimers, and are characterized by Ig-like loops in
the extracellular domain, in which disulphide bridges may form
across protein partners to allow the formation of covalent dimers
which may be constitutively active. FGF receptors have been im-
plicated in achondroplasia, angiogenesis and numerous congen-
ital disorders. At least 22 members of the FGF gene family have
been identified in the human genome [11]. Within this group,
subfamilies of FGF may be divided into canonical, intracellular
and hormone-like FGFs. FGF1-FGF10 have been identified to act
through FGF receptors, while FGF11-14 appear to signal through
intracellular targets. Other family members are less well charac-
terized [194].
Nomenclature fibroblast growth factor receptor 1 fibroblast growth factor receptor 2 fibroblast growth factor receptor 3 fibroblast growth factor receptor 4
Common abreviation FGFR1 FGFR2 FGFR3 FGFR4
HGNC, UniProt FGFR1, P11362 FGFR2, P21802 FGFR3, P22607 FGFR4, P22455
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-4 (FGF4, P08620) >
FGF-5 (FGF5, P12034), FGF-6 (FGF6,
P10767) [145]
FGF-1 (FGF1, P05230) > FGF-4 (FGF4,
P08620), FGF-7 (FGF7, P21781),
FGF-9 (FGF9, P31371) > FGF-2 (FGF2,
P09038), FGF-6 (FGF6, P10767) [145]
FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-9 (FGF9, P31371) >
FGF-4 (FGF4, P08620), FGF-8 (FGF8,
P55075) [145]
FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-4 (FGF4, P08620), FGF-9
(FGF9, P31371) > FGF-6 (FGF6, P10767),
FGF-8 (FGF8, P55075) [145]
(Sub)family-selective
inhibitors
LY2874455 (pIC50 8.6) [208] LY2874455 (pIC50 8.6) [208] LY2874455 (pIC50 8.2) [208] LY2874455 (pIC50 8.2) [208]
Agonists – palifermin – –
Comments: Splice variation of the receptors can influence agonist responses. FGFRL1 (Q8N441) is a truncated kinase-null analogue.
Various antibodies and tyrosine kinase inhibitors have been developed against FGF receptors [107, 210]. PD161570 is an FGFR tyrosine kinase inhibitor [10], while PD173074 has been described to inhibit
FGFR1 and FGFR3 [169].
Type VI RTKs: PTK7/CCK4
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type VI RTKs: PTK7/CCK4
Overview: The PTK7 receptor is associated with polarization of epithelial cells and the development of neural structures. Sequence analysis suggests that the gene product is catalytically inactive as a
protein kinase, although there is evidence for a role in Wnt signalling [152].
Nomenclature protein tyrosine kinase 7 (inactive)
Common abreviation CCK4
HGNC, UniProt PTK7, Q13308
EC number 2.7.10.1
Searchable database: http://www.guidetopharmacology.org/index.jsp Type VI RTKs: PTK7/CCK4 6008
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Comments: Thus far, no selective PTK7 inhibitors have been described.
Type VII RTKs: Neurotrophin receptor/Trk family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type VII RTKs: Neurotrophin receptor/Trk family
Overview: The neurotrophin receptor family of RTKs in-
clude trkA, trkB and trkC (tropomyosin-related kinase) recep-
tors, which respond to NGF, BDNF and neurotrophin-3, re-
spectively. They are associated primarily with proliferative and
migration effects in neural systems. Various isoforms of neu-
rotrophin receptors exist, including truncated forms of trkB and
trkC, which lack catalytic domains. p75(TNFRSF16, also known
as nerve growth factor receptor), which has homologies with
tumour necrosis factor receptors, lacks a tyrosine kinase domain,
but can signal via ceramide release and nuclear factor B (NF-B)
activation. Both trkA and trkB contain two leucine-rich regions
and can exist in monomeric or dimeric forms.
Nomenclature neurotrophic tyrosine kinase, receptor, type 1 neurotrophic tyrosine kinase, receptor, type 2 neurotrophic tyrosine kinase, receptor, type 3
Common abreviation trkA trkB trkC
HGNC, UniProt NTRK1, P04629 NTRK2, Q16620 NTRK3, Q16288
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands NGF (NGF, P01138) > neurotrophin-3 (NTF3, P20783) BDNF (BDNF, P23560), neurotrophin-4 (NTF4, P34130) >
neurotrophin-3 (NTF3, P20783)
–
Endogenous ligands – – neurotrophin-3 (NTF3, P20783)
Inhibitors compound 2c [PMID: 24900538] (pIC50 8.9) [189],
milciclib (pIC50 7.3) [17]
– –
(Sub)family-selective
inhibitors
AZD1332 (pIC50 >8.3) [9], GNF-5837 (pIC50 8) [5] AZD1332 (pIC50 >8.3) [9], GNF-5837 (pIC50 8.1) [5] AZD1332 (pIC50 >8.3) [9], GNF-5837 (pIC50 8.1) [5]
Comments: [125I]NGF (human) and [125I]BDNF (human)
have been used to label the trkA and trkB receptor, respec-
tively. p75 influences the binding of NGF (NGF, P01138) and
neurotrophin-3 (NTF3, P20783) to trkA. The ligand selectivity of
p75 appears to be dependent on the cell type; for example, in
sympathetic neurones, it binds neurotrophin-3 (NTF3, P20783)
with comparable affinity to trkC [40].
Small molecule agonists of trkB have been described, includ-
ing LM22A4 [123], while ANA12 has been described as a non-
competitive antagonist of BDNF binding to trkB [23]. GNF5837
is a family-selective tyrosine kinase inhibitor [4], while the ty-
rosine kinase activity of the trkA receptor can be inhibited by
GW441756 (pIC50= 8.7, [200]) and tyrphostin AG879 [142].
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Type VIII RTKs: ROR family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type VIII RTKs: ROR family
Overview: Members of the ROR family appear to be activated by ligands complexing with other cell-surface proteins. Thus, ROR1 and ROR2 appear to be activated by Wnt-5a (WNT5A, P41221) binding
to a Frizzled receptor thereby forming a cell-surface multiprotein complex [64].
Nomenclature receptor tyrosine kinase-like orphan receptor 1 receptor tyrosine kinase-like orphan receptor 2
Common abreviation ROR1 ROR2
HGNC, UniProt ROR1, Q01973 ROR2, Q01974
EC number 2.7.10.1 2.7.10.1
Type IX RTKs: MuSK
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type IX RTKs: MuSK
Overview: The muscle-specific kinase MuSK is associated with the formation and organisation of the neuromuscular junction from the skeletal muscle side. Agrin (AGRN, O00468) forms a complex with
low-density lipoprotein receptor-related protein 4 (LRP4, O75096) to activate MuSK [89].
Nomenclature muscle, skeletal, receptor tyrosine kinase
Common abreviation MuSK
HGNC, UniProt MUSK, O15146
EC number 2.7.10.1
Comments: Thus far, no selective MuSK inhibitors have been described.
Type X RTKs: HGF (hepatocyte growth factor) receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type X RTKs: HGF (hepatocyte growth factor) receptor family
Overview: HGF receptors regulate maturation of the liver in the embryo, as well as having roles in the adult, for example, in the innate immune system. HGF is synthesized as a single gene product, which
is post-translationally processed to yield a heterodimer linked by a disulphide bridge. The maturation of HGF is enhanced by a serine protease, HGF activating complex, and inhibited by HGF-inhibitor 1
(SPINT1, O43278), a serine protease inhibitor. MST1, the ligand of RON, is two disulphide-linked peptide chains generated by proteolysis of a single gene product.
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Nomenclature MET proto-oncogene, receptor tyrosine kinase macrophage stimulating 1 receptor
Common abreviation MET Ron
HGNC, UniProt MET, P08581 MST1R, Q04912
EC number 2.7.10.1 2.7.10.1
Endogenous ligands hepatocyte growth factor (HGF, P14210) macrophage stimulating protein 1 (MST1, P09603)
Inhibitors capmatinib (pIC50 9.9) [112], SGX-523 (pKd 9.7) [38], PHA-665752
(pKd 9.6) [38], foretinib (pIC50 9.3–9.4) [106, 137], cabozantinib
(pIC50 8.9) [203], foretinib (pKd 8.9) [38], MK-2461 (pIC50 8.6)
[146], BMS-777607 (pIC50 8.4) [164], PHA-665752 (pKi 8.4) [26],
SU11274 (pIC50 8) [190], golvatinib (pIC50 7.8) [139], tivantinib
(pKi 6.4) [135]
BMS-777607 (pIC50 8.7) [164]
Selective inhibitors SGX-523 (pIC50 8.4) [19] –
Comments: PF04217903 is a selective Met tyrosine kinase inhibitor [34].SU11274 is an inhibitor of the HGF receptor [162], with the possibility of further targets [8].
Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family
Overview: Members of this RTK family represented a novel structural motif, when sequenced. The ligands for this family, growth arrest specific protein 6 (GAS6, Q14393) and protein S (PROS1, P07225),
are secreted plasma proteins which undergo vitamin K-dependent post-translational modifications generating carboxyglutamate-rich domains which are able to bind to negatively-charged surfaces of
apoptotic cells.
Nomenclature AXL receptor tyrosine kinase TYRO3 protein tyrosine kinase MER proto-oncogene, tyrosine kinase
Common abreviation Axl Tyro3 Mer
HGNC, UniProt AXL, P30530 TYRO3, Q06418 MERTK, Q12866
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands growth arrest specific protein 6 (GAS6, Q14393) [138],
protein S (PROS1, P07225) [172]
growth arrest specific protein 6 (GAS6, Q14393) [138],
protein S (PROS1, P07225) [172]
growth arrest specific protein 6 (GAS6, Q14393) [138]
Comments: AXL tyrosine kinase inhibitors have been described [130].
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family 6011
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Type XII RTKs: TIE family of angiopoietin receptors
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XII RTKs: TIE family of angiopoietin receptors
Overview: The TIE family were initially associated with formation of blood vessels. Endogenous ligands are angiopoietin-1 (ANGPT1, Q15389), angiopoietin-2 (ANGPT2, O15123), and angiopoietin-4
(ANGPT4, Q9Y264). Angiopoietin-2 (ANGPT2, O15123) appears to act as an endogenous antagonist of angiopoietin-1 function.
Nomenclature tyrosine kinase with immunoglobulin-like and EGF-like domains 1 TEK tyrosine kinase, endothelial
Common abreviation TIE1 TIE2
HGNC, UniProt TIE1, P35590 TEK, Q02763
EC number 2.7.10.1 2.7.10.1
Endogenous ligands – angiopoietin-1 (ANGPT1, Q15389), angiopoietin-4 (ANGPT4, Q9Y264)
Type XIII RTKs: Ephrin receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XIII RTKs: Ephrin receptor family
Overview: Ephrin receptors are a family of 15 RTKs
(the largest family of RTKs) with two identified subfami-
lies (EphA and EphB), which have a role in the regula-
tion of neuronal development, cell migration, patterning
and angiogenesis. Their ligands are membrane-associated
proteins, thought to be glycosylphosphatidylinositol-linked
for EphA (ephrin-A1 (EFNA1, P20827) , ephrin-A2 (EFNA2,
O43921), ephrin-A3 (EFNA3, P52797), ephrin-A4 (EFNA4,
P52798) and ephrin-A5 (EFNA5, P52803)) and 1TM proteins for
Ephrin B (ENSFM00250000002014: ephrin-B1 (EFNB1, P98172),
ephrin-B2 (EFNB2, P52799) and ephrin-B3 (EFNB3, Q15768)), al-
though the relationship between ligands and receptors has been
incompletely defined.
Nomenclature EPH receptor A1 EPH receptor A2 EPH receptor A3 EPH receptor A4 EPH receptor A5 EPH receptor A6 EPH receptor A7
Common abreviation EphA1 EphA2 EphA3 EphA4 EphA5 EphA6 EphA7
HGNC, UniProt EPHA1, P21709 EPHA2, P29317 EPHA3, P29320 EPHA4, P54764 EPHA5, P54756 EPHA6, Q9UF33 EPHA7, Q15375
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
Inhibitors compound 20
[PMID: 23489211]
(pIC50 5.6) [79]
– – – – – –
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XIII RTKs: Ephrin receptor family 6012
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Nomenclature EPH receptor A8 EPH receptor A10 EPH receptor B1 EPH receptor B2 EPH receptor B3 EPH receptor B4 EPH receptor B6
Common abreviation EphA8 EphA10 EphB1 EphB2 EphB3 EphB4 EphB6
HGNC, UniProt EPHA8, P29322 EPHA10, Q5JZY3 EPHB1, P54762 EPHB2, P29323 EPHB3, P54753 EPHB4, P54760 EPHB6, O15197
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
Inhibitors
– –
compound 66
[PMID: 19788238]
(pIC50 9) [97]
– – XL-647 (pIC50 8.9)
[57]
–
Type XIV RTKs: RET
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XIV RTKs: RET
Overview: Ret proto-oncogene (Rearranged during transfection) is a transmembrane tyrosine kinase enzyme which is employed as a signalling partner for members of the GDNF family receptors. Ligand-
activated GFR appears to recruit Ret as a dimer, leading to activation of further intracellular signalling pathways. Ret appears to be involved in neural crest development, while mutations may be involved
in multiple endocrine neoplasia, Hirschsprung’s disease, and medullary thyroid carcinoma.
Nomenclature ret proto-oncogene
Common abreviation Ret
HGNC, UniProt RET, P07949
EC number 2.7.10.1
Inhibitors tamatinib (pIC50 8.3) [27], vandetanib (pKd 7.5) [38], vandetanib (pIC50 7) [22]
Comments: A number of tyrosine kinase inhibitors targeting RET have been described [47].
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XIV RTKs: RET 6013
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Type XV RTKs: RYK
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XV RTKs: RYK
Overview: The ‘related to tyrosine kinase receptor’ (Ryk) is structurally atypical of the family of RTKs, particularly in the activation and ATP-binding domains. RYK has been suggested to lack kinase
activity and appears to be involved, with FZD8, in the Wnt signalling system [152].
Nomenclature receptor-like tyrosine kinase
Common abreviation RYK
HGNC, UniProt RYK, P34925
EC number 2.7.10.1
Comments: Thus far, no selective RYK inhibitors have been described.
Type XVI RTKs: DDR (collagen receptor) family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XVI RTKs: DDR (collagen receptor) family
Overview: Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are structurally-related membrane protein tyrosine kinases activated by collagen. Collagen is probably the most abundant protein in
man, with at least 29 families of genes encoding proteins, which undergo splice variation and post-translational processing, and may exist in monomeric or polymeric forms, producing a triple-stranded,
twine-like structure. In man, principal family members include COL1A1 (COL1A1, P02452), COL2A1 (COL2A1, P02458), COL3A1 (COL3A1, P02461) and COL4A1 (COL4A1, P02462).
Nomenclature discoidin domain receptor tyrosine kinase 1 discoidin domain receptor tyrosine kinase 2
Common abreviation DDR1 DDR2
HGNC, UniProt DDR1, Q08345 DDR2, Q16832
EC number 2.7.10.1 2.7.10.1
Inhibitors compound 7k [PMID: 23521020] (pIC50 8.6) [51] –
Comments: The tyrosine kinase inhibitors of DDR, imatinib and nilotinib, were identified from proteomic analysis [39]. Other collagen receptors include glycoprotein VI (Q9HCN6), leukocyte-associated
immunoglobulin-like receptor 1 (Q6GTX8), leukocyte-associated immunoglobulin-like receptor 2 (Q6ISS4) and osteoclast-associated immunoglobulin-like receptor (Q8IYS5).
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XVI RTKs: DDR (collagen receptor) family 6014
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Type XVII RTKs: ROS receptors
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XVII RTKs: ROS receptors
Nomenclature c-ros oncogene 1, receptor tyrosine kinase
Common abreviation ROS
HGNC, UniProt ROS1, P08922
EC number 2.7.10.1
Comments: crizotinib is a tyrosine kinase inhibitor, anti-cancer drug targeting ALK and ROS1.
Type XVIII RTKs: LMR family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XVIII RTKs: LMR family
Overview: The LMR kinases are unusual amongst the RTKs in possessing a short extracellular domain and extended intracellular domain (hence the ‘Lemur’ name reflecting the long tail). A precise
function for these receptors has yet to be defined, although LMR1 was identified as a potential marker of apoptosis [52], giving rise to the name AATYK (Apoptosis-associated tyrosine kinase); while
over-expression induces differentiation in neuroblastoma cells [156].
Nomenclature apoptosis-associated tyrosine kinase lemur tyrosine kinase 2 lemur tyrosine kinase 3
Common abreviation Lmr1 Lmr2 Lmr3
HGNC, UniProt AATK, Q6ZMQ8 LMTK2, Q8IWU2 LMTK3, Q96Q04
EC number 2.7.11.1 2.7.11.1 2.7.11.1
Comments: As yet no selective inhibitors of the LMR family have been described.
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XVIII RTKs: LMR family 6015
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Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family
Overview: The LTK family appear to lack endogenous ligands. LTK is subject to tissue-specific splice variation, which appears to generate products in distinct subcellular locations. ALK fusions created
by gene translocations and rearrangements are associated with many types of cancer, including large cell lymphomas, inflammatory myofibrilastic tumours and non-small cell lung cancer [120].
Nomenclature leukocyte receptor tyrosine kinase anaplastic lymphoma receptor tyrosine kinase
Common abreviation LTK ALK
HGNC, UniProt LTK, P29376 ALK, Q9UM73
EC number 2.7.10.1 2.7.10.1
Inhibitors – GSK-1838705A (pIC50 9.3) [161], compound 8e [PMID: 24432909] (pIC50
9.1) [76], crizotinib (pIC50 9) [35], NVP-TAE684 (pKd 9) [38],
compound 25b [PMID: 22564207] (pIC50 8.7) [59]
Selective inhibitors – ceritinib (pIC50 9.7) [120]
Comments – crizotinib appears to be a selective ALK inhibitor acting on the tyrosine kinase
activity [58]
Type XX RTKs: STYK1
Catalytic receptors! Receptor kinases! TK: Tyrosine kinase! Receptor tyrosine kinases! Type XX RTKs: STYK1
Overview: Similar to the LMR RTK family, STYK1 has a truncated extracellular domain, but also displays a relatively short intracellular tail beyond the split kinase domain. STYK1 (also known as Novel
Oncogene with Kinase-domain, NOK) has been suggested to co-localize with activated EGF receptor [43].
Nomenclature serine/threonine/tyrosine kinase 1
Common abreviation STYK1
HGNC, UniProt STYK1, Q6J9G0
EC number 2.7.10.2
Comments: As yet, no selective inhibitors of STYK1 have been described.
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XX RTKs: STYK1 6016
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Receptor tyrosine phosphatases (RTP)
Catalytic receptors! Receptor tyrosine phosphatases (RTP)
Overview: Receptor tyrosine phosphatases (RTP) are cell-surface proteins with a single TM region and intracellular phosphotyrosine phosphatase activity. Many family members exhibit constitutive
activity in heterologous expression, dephosphorylating intracellular targets such as Src tyrosine kinase (SRC) to activate signalling cascades. Family members bind components of the extracellular matrix
or cell-surface proteins indicating a role in intercellular communication. Listed here are those family members with putative endogenous ligands.
Nomenclature RTP Type C RTP Type D RTP Type F RTP Type G
HGNC, UniProt PTPRC, P08575 PTPRD, P23468 PTPRF, P10586 PTPRG, P23470
Putative endogenous
ligands
galectin-1 (LGALS1, P09382)
[188]
netrin-G3 ligand (LRRC4B,
Q9NT99) [96]
netrin-G3 ligand (LRRC4B,
Q9NT99) [96]
contactin-3 (CNTN3, Q9P232),
contactin-4 (CNTN4, Q8IWV2),
contactin-5 (CNTN5, O94779),
contactin-6 (CNTN6, Q9UQ52)
[16]
Nomenclature RTP Type K RTP Type S RTP Type Z1
HGNC, UniProt PTPRK, Q15262 PTPRS, Q13332 PTPRZ1, P23471
Putative endogenous
ligands
galectin-3 (LGALS3, P17931),
galectin-3 binding protein
(LGALS3BP, Q08380) [90]
chondroitin sulphate proteoglycan 3
(NCAN, O14594),
netrin-G3 ligand (LRRC4B,
Q9NT99) [96, 166]
contactin-1 (CNTN1, Q12860),
pleiotrophin (PTN, C9JR52) (acts
as a negative regulator) [16, 127]
Further Reading
Böhmer F et al. (2013) Protein tyrosine phosphatase structure-function relationships in regulation
and pathogenesis. FEBS J. 280: 413-31 [PMID:22682070]
Dushek O et al. (2012) Non-catalytic tyrosine-phosphorylated receptors. Immunol. Rev. 250: 258-76
[PMID:23046135]
He R et al. (2013) Small molecule tools for functional interrogation of protein tyrosine phosphatases.
FEBS J. 280: 731-50 [PMID:22816879]
Julien SG et al. (2011) Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 11: 35-49
[PMID:21179176]
Mohebiany AN et al. (2013) Receptor-type tyrosine phosphatase ligands: looking for the needle in
the haystack. FEBS J. 280: 388-400 [PMID:22682003]
Sastry SK et al. (2011) Checks and balances: interplay of RTKs and PTPs in cancer progression.
Biochem. Pharmacol. 82: 435-40 [PMID:21704606]
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Tumour necrosis factor (TNF) receptor family
Catalytic receptors! Tumour necrosis factor (TNF) receptor family
Overview: The TNF receptor superfamily (TNFRSF, provisional
nomenclature) displays limited homology beyond an extracel-
lular domain rich in cysteine residues and is activated by at
least 18 different human homologues of TNF referred to as
the TNF superfamily (TNFSF). Some homologues lacking trans-
membrane and cytoplasmic domains function as decoy recep-
tors binding ligand without inducing cell signalling. Many of
these receptors and ligands function as multimeric entities. Sig-
nalling through these receptors is complex and involves inter-
action with cytoplasmic adaptor proteins (such as TRADD and
TRAF1). Several of these receptors contain cytoplasmic motifs
known as ‘death domains’, which upon activation serve to recruit
death domain- and death effector domain-containing proteins
crucial for the initiation of an apoptotic response. Additional
signalling pathways include the regulation of the nuclear factor
B or mitogen-activated protein kinase pathways. Pharmacolog-
ical manipulation of these receptors is mainly enacted through
chelating the endogenous agonists with humanised monoclonal
antibodies (e.g. Infliximab or adalimumab) or recombinant fu-
sion proteins of IgG and soluble receptors (e.g. etanercept). Some
mutated forms of TNF ligands are capable of selecting for differ-
ent receptor subtypes.
Nomenclature tumor necrosis factor receptor 1 tumor necrosis factor receptor 2 lymphotoxin β receptor OX40 CD40
Systematic
nomenclature
TNFRSF1A TNFRSF1B TNFRSF3 TNFRSF4 TNFRSF5
Common
abreviation
TNFR1 TNFR2 – – –
HGNC, UniProt TNFRSF1A, P19438 TNFRSF1B, P20333 LTBR, P36941 TNFRSF4, P43489 CD40, P25942
Adaptor proteins TRADD TRAF1, TRAF2, TRAF5 TRAF3, TRAF4, TRAF5 TRAF1, TRAF2, TRAF3,
TRAF5
TRAF1, TRAF2,
TRAF3, TRAF5,
TRAF6
Endogenous
ligands
lymphotoxin-α (LTA, P01374),
tumour necrosis factor
membrane form
(TNF, P01375),
tumour necrosis factor
shed form
(TNF, P01375)
lymphotoxin-α (LTA, P01374),
tumour necrosis factor
membrane form
(TNF, P01375)
LIGHT (TNFSF14, O43557),
lymphotoxin β2α1 heterotrimer
(LTA LTB, P01374 Q06643)
OX-40 ligand (TNFSF4,
P23510)
CD40 ligand
(CD40LG,
P29965)
Searchable database: http://www.guidetopharmacology.org/index.jsp Tumour necrosis factor (TNF) receptor family 6018
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Nomenclature Fas decoy receptor 3 CD27 CD30 4-1BB
Systematic nomenclature TNFRSF6 TNFRSF6B TNFRSF7 TNFRSF8 TNFRSF9
HGNC, UniProt FAS, P25445 TNFRSF6B, O95407 CD27, P26842 TNFRSF8, P28908 TNFRSF9, Q07011
Adaptor proteins FADD – TRAF2, SIVA TRAF1, TRAF2, TRAF3,
TRAF5
TRAF1, TRAF2, TRAF3
Endogenous ligands Fas ligand (FASLG,
P48023)
– CD70 (CD70, P32970) CD30 ligand (TNFSF8,
P32971)
4-1BB ligand (TNFSF9,
P41273)
Antibodies – – – brentuximab vedotin
(Inhibition)
–
Comments – Decoy receptor for LIGHT
(TNFSF14, O43557), TL1A
(TNFSF15, O95150) and
Fas ligand (FASLG,
P48023).
– – –
Nomenclature death receptor 4 death receptor 5 decoy receptor 1 decoy receptor 2 receptor activator of NF-kappa B
Systematic
nomenclature
TNFRSF10A TNFRSF10B TNFRSF10C TNFRSF10D TNFRSF11A
Common
abreviation
DR4 DR5 – – RANK
HGNC, UniProt TNFRSF10A, O00220 TNFRSF10B,
O14763
TNFRSF10C, O14798 TNFRSF10D,
Q9UBN6
TNFRSF11A, Q9Y6Q6
Adaptor proteins FADD FADD – – TRAF1, TRAF2, TRAF3, TRAF5, TRAF6
Endogenous
ligands
TRAIL (TNFSF10, P50591) TRAIL (TNFSF10,
P50591)
– – RANK ligand (TNFSF11, O14788)
Comments – – Decoy receptor for TRAIL
(TNFSF10, P50591).
Decoy receptor
for TRAIL
(TNFSF10,
P50591).
–
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Nomenclature osteoprotegerin death receptor 3 TWEAK receptor TACI
Systematic nomenclature TNFRSF11B TNFRSF25 TNFRSF12A TNFRSF13B
Common abreviation OPG DR3 – –
HGNC, UniProt TNFRSF11B, O00300 TNFRSF25, Q93038 TNFRSF12A, Q9NP84 TNFRSF13B, O14836
Adaptor proteins – TRADD TRAF1, TRAF2, TRAF3 TRAF2, TRAF5, TRAF6
Endogenous ligands – TL1A (TNFSF15, O95150) TWEAK (TNFSF12, O43508) APRIL (TNFSF13,
O75888), BAFF
(TNFSF13B, Q9Y275)
Comments Acts as a decoy receptor for
RANK ligand (TNFSF11, O14788)
and possibly for TRAIL (TNFSF10,
P50591).
– – –
Nomenclature BAFF receptor herpes virus entry mediator nerve growth factor receptor B cell maturation antigen
Systematic nomenclature TNFRSF13C TNFRSF14 TNFRSF16 TNFRSF17
Common abreviation BAFF-R HVEM – BCMA
HGNC, UniProt TNFRSF13C, Q96RJ3 TNFRSF14, Q92956 NGFR, P08138 TNFRSF17, Q02223
Adaptor proteins TRAF3 TRAF2, TRAF3, TRAF5 TRAF2, TRAF4, TRAF6 TRAF1, TRAF2, TRAF3, TRAF5,
TRAF6
Endogenous ligands BAFF (TNFSF13B, Q9Y275) B and T lymphocyte attenuator
(BTLA, Q7Z6A9), LIGHT (TNFSF14,
O43557), lymphotoxin-α (LTA,
P01374)
BDNF (BDNF, P23560), NGF
(NGF, P01138), neurotrophin-3
(NTF3, P20783), neurotrophin-4
(NTF4, P34130)
APRIL (TNFSF13, O75888), BAFF
(TNFSF13B, Q9Y275)
Nomenclature glucocorticoid-induced TNF receptor toxicity and JNK inducer RELT death receptor 6
Systematic nomenclature TNFRSF18 TNFRSF19 TNFRSF19L TNFRSF21
Common abreviation GITR TAJ – DR6
HGNC, UniProt TNFRSF18, Q9Y5U5 TNFRSF19, Q9NS68 RELT, Q969Z4 TNFRSF21, O75509
Adaptor proteins TRAF1, TRAF2, TRAF3, SIVA TRAF1, TRAF2, TRAF3, TRAF5 TRAF1 TRADD
Endogenous ligands TL6 (TNFSF18, Q9UNG2) lymphotoxin-α (LTA, P01374) – –
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Nomenclature TNFRSF22 TNFRSF23 ectodysplasin A2 isoform receptor ectodysplasin 1, anhidrotic receptor
Systematic nomenclature – – TNFRS27 –
HGNC, UniProt – – EDA2R, Q9HAV5 EDAR, Q9UNE0
Adaptor proteins – – TRAF1, TRAF3, TRAF6 TRAF1, TRAF2, TRAF3
Endogenous ligands – – ectodysplasin A2 (EDA, Q92838) [204] ectodysplasin A1 (EDA, Q92838) [204]
Comments: TNFRSF1A is preferentially activated by the
shed form of TNF ligand, whereas the membrane-bound form
of TNF serves to activate TNFRSF1A and TNFRSF1B equally.
The neurotrophins nerve growth factor (NGF (NGF, P01138)),
brain-derived neurotrophic factor (BDNF (BDNF, P23560)),
neurotrophin-3 (NTF3, P20783) (NTF3) and neurotrophin-4
(NTF4, P34130) (NTF4) are structurally unrelated to the TNF lig-
and superfamily but exert some of their actions through the
“low affinity nerve growth factor receptor” (NGFR (TNFRSF16))
as well as through the TRK family of receptor tyrosine kinases.
The endogenous ligands for EDAR and EDA2R are, respectively,
the membrane (Q92838[1-391]) and secreted (Q92838[160-391])
isoforms of Ectodysplasin-A (EDA, Q92838).
Further Reading
Aggarwal BB. (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev.
Immunol. 3: 745-56 [PMID:12949498]
Ashkenazi A. (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily.
Nat. Rev. Cancer 2: 420-30 [PMID:12189384]
Mahmood Z et al. (2010) Death receptors: targets for cancer therapy. Exp. Cell Res. 316: 887-99
[PMID:20026107]
Rickert RC et al. (2011) Signaling by the tumor necrosis factor receptor superfamily in B-cell biology
and disease. Immunol. Rev. 244: 115-33 [PMID:22017435]
Tansey MG et al. (2009) The TNF superfamily in 2009: new pathways, new indications, and new
drugs. Drug Discov. Today 14: 1082-8 [PMID:19837186]
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